{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:38:59Z","timestamp":1782398339850,"version":"3.54.5"},"reference-count":1150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T00:00:00Z","timestamp":1461801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.pharmthera.2016.03.019","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T21:34:04Z","timestamp":1461965644000},"page":"1-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease"],"prefix":"10.1016","volume":"164","author":[{"given":"Martin C.","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans R.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.03.019_bb0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.EHX.0000414803.54664.e5","article-title":"Comparative study on the effects of grape seed extract and telmisartan on doxorubicin-induced cardiotoxicity in adult male rats: Light and electron microscopic study","volume":"35","author":"Abd El Samad","year":"2012","journal-title":"Egypt J Histol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.trsl.2014.06.003","article-title":"Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes","volume":"164","author":"Abdelsaid","year":"2014","journal-title":"Transl Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0015","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/01.CIR.96.6.1906","article-title":"Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: A link between angiotensin II and intimal thickening","volume":"96","author":"Abe","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.301.1.21","article-title":"The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension","volume":"301","author":"Abrahamsen","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1161\/HYPERTENSIONAHA.108.118935","article-title":"Excess dietary salt alters angiotensinergic regulation of neurons in the rostral ventrolateral medulla","volume":"52","author":"Adams","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.RES.84.4.458","article-title":"Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes","volume":"84","author":"Aikawa","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jjcc.2008.07.018","article-title":"Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-ss inhibition and apoptosis induction in spontaneously hypertensive rats","volume":"52","author":"Akashiba","year":"2008","journal-title":"J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0040","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5897\/AJPP11.005","article-title":"Amelioration of chronic cyclosporin A-induced nephrotoxicity by telmisartan in rats","volume":"5","author":"Al-Amran","year":"2011","journal-title":"Afr J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0045","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diacare.46.10.1612","article-title":"Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/jm9604383","article-title":"Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles","volume":"40","author":"Almansa","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy","volume":"36","author":"Alter","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0060","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00005344-199903000-00014","article-title":"Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle","volume":"33","author":"Ambrose","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.HYP.21.1.29","article-title":"Angiotensin II causes mesangial cell hypertrophy","volume":"21","author":"Anderson","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0070","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/10641969709083199","article-title":"Angiotensin II antagonism and pre-glomerular arterial wall dimensions in the kidney of the spontaneously hypertensive rat","volume":"19","author":"Anderson","year":"1997","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0075","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","article-title":"Effect of inhibition of the renin\u2013angiotensin system on developtment of type 2 diabetes mellitus (meta-analysis of randomized trials)","volume":"99","author":"Andraws","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0024-3205(00)00648-2","article-title":"Effects of irbesartan and bosentan on the blood pressure and adrenal zona glomerulosa function in heterozygous transgenic TGR(mREN2)27 rats","volume":"67","author":"Andreis","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0085","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/bj3470275","article-title":"Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro","volume":"347","author":"Aoki","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0095","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/ATVBAHA.112.249516","article-title":"Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-\/- mice","volume":"32","author":"Aono","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.HYP.0000225402.69580.1d","article-title":"Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice","volume":"48","author":"Araki","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00380-010-0005-4","article-title":"The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet","volume":"25","author":"Aritomi","year":"2010","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tox.2010.09.013","article-title":"Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-\u03b3 agonist actions","volume":"279","author":"Arozal","year":"2011","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.04.007","article-title":"Different muscarinic receptor subtypes modulate proliferation of primary human smooth detrusor smooth muscle cells via Akt\/PI3K and MAP kinases","volume":"74","author":"Arrighi","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0120","first-page":"1055","article-title":"Inhibitory action of telmisartan on constriction of rat mesenteric artery in vitro","volume":"34","author":"Asano","year":"2006","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biomag.2013.08.001","article-title":"Amelioration of cardiac hypertrophy induced by abdominal aortic banding in ferulic acid treated rats","volume":"3","author":"Aswar","year":"2013","journal-title":"Biomed Aging Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1756-3305-6-199","article-title":"Telmisartan, an AT1 receptor blocker and PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection","volume":"6","author":"Attia","year":"2013","journal-title":"Parasite Vectors"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.metabol.2009.07.002","article-title":"Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain","volume":"59","author":"Aubert","year":"2010","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1476-5381.1992.tb14392.x","article-title":"Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan","volume":"106","author":"Azuma","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2008.06.023","article-title":"Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium","volume":"373","author":"Baden","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin\u2013angiotensin\u2013aldosterone systems: Targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0155","first-page":"F937","article-title":"Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells","volume":"264","author":"Bakris","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0160","first-page":"68","article-title":"Telmisartan protects the lipopolysaccharide intoxicated RAW 264.7 cell line by deactivating NF\u03baB mediated inflammatory mechanism","volume":"6","author":"Balaji","year":"2014","journal-title":"J Pharm Sci Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0165","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","article-title":"Submaximal PPAR\u03b3 activation and endothelial dysfunction: New perspectives for the management of cardiovascular disorders","volume":"166","author":"Balakumar","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00005344-200107000-00015","article-title":"Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery","volume":"38","author":"Balt","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00005344-200207000-00007","article-title":"Prejunctinal and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery","volume":"40","author":"Balt","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00004872-200103000-00015","article-title":"Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: A comparison between losartan, irbesartan, telmisartan and captopril","volume":"19","author":"Balt","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0185","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/00004872-200112000-00018","article-title":"Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: Comparison between valsartan, candesartan, eprosartan and embusartan","volume":"19","author":"Balt","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0190","first-page":"525","article-title":"Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats","volume":"50","author":"Barone","year":"2001","journal-title":"CVR"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0195","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12012-012-9156-0","article-title":"Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats","volume":"12","author":"Bayir","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0200","first-page":"F74","article-title":"Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II","volume":"264","author":"Baylis","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjp.0707652","article-title":"Cardiovascular reactivity after blockade of angiotensin AT1 receptors in the experimental model of tilting test in conscious rats","volume":"153","author":"Bedette","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0210","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00004872-200403000-00022","article-title":"Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattactant protein-1 and inflammation in hypertensive heart disease","volume":"22","author":"Behr","year":"2004","journal-title":"J Hypertens"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0215","first-page":"S225","article-title":"Angiotensin II stimulates macula densa basolateral sodium\/hydrogen exchange via type 1 angiotensin II receptors","volume":"10","author":"Bell","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0220","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3317\/jraas.2000.063","article-title":"The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man","volume":"1","author":"Belz","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/cp.1999.v66.a101162","article-title":"Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay","volume":"66","author":"Belz","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2016.03.019_bb0230","first-page":"S45","article-title":"Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilextil and losartan in healthy human volunteers","volume":"11","author":"Belz","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0235","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s10571-012-9862-y","article-title":"Six commercially available angiotensin II AT1 receptor antibodies are non-specific","volume":"32","author":"Benicky","year":"2012","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0240","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI36703","article-title":"Disruptino of the Ang II type 1 receptor promotes longevity in mice","volume":"119","author":"Benigni","year":"2009","journal-title":"J Clin Invest"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0245","first-page":"S104","article-title":"Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats","volume":"10","author":"Bennai","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0250","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FJC.0b013e31811dfbe7","article-title":"Telmisartan improves endothelial function in patients with essential hypertension","volume":"50","author":"Benndorf","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0255","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/HJH.0b013e3282f56ba5","article-title":"Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same?","volume":"26","author":"Benson","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0260","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/oby.20122","article-title":"Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats","volume":"21","author":"Bentzen","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0265","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1021\/jm00074a018","article-title":"A new series of imidazolones: Highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists","volume":"36","author":"Bernhart","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.112.006809","article-title":"A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme","volume":"65","author":"Bernstein","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0275","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/0886022X.2010.504911","article-title":"Role of fenofibrate alone and in combination with telmisartan on renal ischemia\/reperfusion injury","volume":"32","author":"Bhalodia","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jphs.09202FP","article-title":"Constituively active mutant of N111G of angiotensin II type 1 (AT1) receptor induces homologous internalization through mediation of AT1-receptor antagonist","volume":"111","author":"Bhuiyan","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0285","first-page":"275","article-title":"Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl\/Rapp rats","volume":"62","author":"Biala","year":"2011","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0290","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1248\/bpb.32.416","article-title":"Telmisartan increases the permeability of endothelial cells through zonula occludens-1","volume":"32","author":"Bian","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0295","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.phrs.2012.07.001","article-title":"The combined strategy with PPAR\u03b1 agonism and AT1 receptor antagonistm is not superior relative to their individual traetment approach in preventing the induction of nephropathy in the diabetic rat","volume":"66","author":"Bishnoi","year":"2012","journal-title":"Pharmacol Res"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0300","first-page":"S98","article-title":"Effects of candesartan and PD123319 on responses to angiotensin II in the anesthetized mouse","volume":"10","author":"Bivalacqua","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0305","first-page":"H780","article-title":"Stretch-induced hypertrophy of isolated adult rabbit cardiomyocytes","volume":"299","author":"Blaauw","year":"2010","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0310","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0014-2999(00)00070-4","article-title":"Endogenous renin and related short-term blood pressure variability in the conscious rat","volume":"394","author":"Blanc","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0315","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2007.10.037","article-title":"Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice","volume":"199","author":"Blessing","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1470320309358108","article-title":"Endothelin-1 receptor blockade induces upregulation of renin\u2013angiotensin\u2013aldosterone system expression in terms of blood pressure regulation","volume":"11","author":"Bo","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0325","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/00004872-199508000-00010","article-title":"Angiotensin II receptor blockade in TGR(mREN2)27: Effects of renin\u2013angiotensin-system gene expression and cardiovascular functions","volume":"13","author":"B\u00f6hm","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5603\/FHC.2012.0014","article-title":"Atrial expression of the CCN1 and CCN2 proteins in chronic heart failure","volume":"50","author":"Bonda","year":"2012","journal-title":"Folia Histochem Cytobiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pharep.2014.08.019","article-title":"Transcriptional and post-transcriptional regulation of CCN genes in failing heart","volume":"67","author":"Bonda","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0340","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0345","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.HYP.28.4.635","article-title":"Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy","volume":"28","author":"Booz","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0350","first-page":"R181","article-title":"AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity","volume":"289","author":"Boustany","year":"2005","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2369-11-31","article-title":"Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis","volume":"11","author":"Bramlage","year":"2010","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0360","first-page":"F409","article-title":"Resetting of exaggerated tubuloglomerular feedback activity in acutely volume-expanded young SHR","volume":"276","author":"Br\u00e4nnstr\u00f6m","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0365","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.HYP.22.5.699","article-title":"Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors","volume":"22","author":"Brasch","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0370","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1681\/ASN.V391583","article-title":"Erythropoietin-induced anti-natriuresis medicated by angiotensin in perfused kidneys","volume":"3","author":"Brier","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0375","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00004872-199715066-00004","article-title":"Renin\u2013angiotensin system and myocardial collagen matrix: Modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism","volume":"15","author":"Brilla","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0380","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.HYP.32.4.746","article-title":"Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure","volume":"32","author":"Brodsky","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0385","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ajh.2009.171","article-title":"Production and secretion of adiponectin from 3T3-L1 adipocytes: Comparison of antihypertensive drugs","volume":"22","author":"Brody","year":"2009","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0390","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0022-3565(25)10366-2","article-title":"Effect of captopril and the nonpeptide angiotensin Ii antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis","volume":"263","author":"Brooks","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0395","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF00164582","article-title":"Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs","volume":"345","author":"Brooks","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0400","first-page":"S143","article-title":"Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin\u2013angiotensin system","volume":"10","author":"Brown","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0405","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jvim.12471","article-title":"Telmisartan treatment of refractory proteinuria in a dog","volume":"28","author":"Bugbee","year":"2014","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0410","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1021\/jm00114a021","article-title":"Nonpeptidic angiotensin II antagonists: Synthesis and in vitro activity of a series of novel naphtalene and tetrahydronaphtalene derivatives","volume":"34","author":"Buhlmayer","year":"1991","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0415","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1111\/j.1476-5381.1995.tb15122.x","article-title":"Lack of a centrally-mediated antihypertensive effect following acute or chronic treatment with AT-1 receptor antagonists in spontaneously hypertensive rats","volume":"116","author":"Bunting","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0420","first-page":"H2482","article-title":"AT1-receptor blockade enhances ischemic preconditioning in hypertrophied rat myocardium","volume":"277","author":"Butler","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0425","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.HYP.19.2.138","article-title":"Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension","volume":"19","author":"Cachofeiro","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0430","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.HYP.25.5.1014","article-title":"Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat","volume":"25","author":"Campbell","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0435","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00210-006-0087-9","article-title":"How valid are animal models to evaluate treatments for pulmonary hypertension?","volume":"373","author":"Campian","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0440","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.108.061366","article-title":"Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats","volume":"50","author":"Campian","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0445","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/cs1000591","article-title":"Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats","volume":"100","author":"Cao","year":"2001","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0450","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/01.HYP.36.4.561","article-title":"Blocakde of the renin\u2013angiotensin and endothelin systems on progressive renal injury","volume":"36","author":"Cao","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0455","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.34.3.408","article-title":"Role of angiotensin receptor subtypes in mesenteric vascular prolfieration and hypertrophy","volume":"34","author":"Cao","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0460","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00004872-199816060-00010","article-title":"Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action","volume":"16","author":"Cao","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0465","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3760\/cma.j.issn.0366-6999.20122896","article-title":"Telmisartan promotes proliferation and differentiation of endothelial progenitor cells via activation of Akt","volume":"127","author":"Cao","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0470","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","article-title":"Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium","volume":"24","author":"Carbajo-Lozoya","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0475","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00005344-199903000-00016","article-title":"Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF\/Mccc-facp rats","volume":"33","author":"Carraway","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0480","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/ajh\/hpu201","article-title":"Azilsartan is associated with increased circulating angiotensin-(1\u20137) levels and reduced reovascular 20-HETE levels","volume":"28","author":"Carroll","year":"2015","journal-title":"Am J Hypertens"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0485","first-page":"S230","article-title":"Candesartan and progression of preglomerular lesions in N(G)-nitrol-L-arginine methyl ester hypertensive rats","volume":"10","author":"Casellas","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0490","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00424-009-0725-4","article-title":"Angiotensin receptors as determinants of life span","volume":"459","author":"Cassis","year":"2010","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0495","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-3565(25)38210-8","article-title":"Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist","volume":"265","author":"Cazaubon","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0500","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/01.HYP.33.1.102","article-title":"Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidney of Goldblatt hypertensive rats","volume":"33","author":"Cervenka","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0505","first-page":"F940","article-title":"Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats","volume":"274","author":"Cervenka","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0510","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/01.HYP.30.5.1260","article-title":"Analysis of the effects of candesartan in the mesenteric vascular bed of the cat","volume":"30","author":"Champion","year":"1997","journal-title":"Hypertension"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0515","first-page":"S101","article-title":"Analysis of the effects of candesartan on responses to angiotensin II in the hindquartes vascular bed of the cat","volume":"10","author":"Champion","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl. 10","key":"10.1016\/j.pharmthera.2016.03.019_bb0520","first-page":"S95","article-title":"The influence of candesartan and PD123319 on response to angiotensin II in the hindquarters vascular bed of the rat","volume":"10","author":"Champion","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0525","first-page":"E115","article-title":"Responses to angiotensin peptides are mediated by AT1 receptors in the rat","volume":"274","author":"Champion","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0530","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ajh\/5.6.354","article-title":"Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog","volume":"5","author":"Chan","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0535","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MAJ.0b013e31822993ff","article-title":"Angiotensin II type-1 receptor-JAK\/STAT pathway mediates induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy","volume":"343","author":"Chang","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0540","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/S0022-3565(25)38287-X","article-title":"Intrinsic properties of the nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations","volume":"265","author":"Chansel","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0545","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0922-4106(93)90077-M","article-title":"Characterization of [3H]losartan receptors in isolated rat glomeruli","volume":"247","author":"Chansel","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0550","first-page":"F853","article-title":"Angiotensin receptor sites in renal vasculature of rats developing genetic hypertension","volume":"265","author":"Chatziantoniou","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0555","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.atherosclerosis.2008.07.032","article-title":"Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques","volume":"203","author":"Chatzizisis","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0560","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/10641963.2014.881842","article-title":"Effect of telmisartan on VEGF-induced and VEGF-independent angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ)-induced diabetic rats","volume":"36","author":"Chaudagar","year":"2014","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0565","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1097\/HJH.0b013e3283649b4d","article-title":"Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-cliip hypertension","volume":"31","author":"Chaykovska","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0570","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1111\/bph.13029","article-title":"The peroxisome proliferator-activated receptors in cardiovascular diseases: Experimental benefits and clinical challenges","volume":"172","author":"Cheang","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0575","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/10641969609081771","article-title":"Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor","volume":"18","author":"Chen","year":"1996","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0580","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1111\/bph.12736","article-title":"Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53","volume":"171","author":"Chen","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0585","first-page":"522","article-title":"Telmisartan counteracts TGF-\u03b21 induced epithelial-to-mesenchymal transition via PPAR-\u03b3 in human proximal tubule epithelial cells","volume":"5","author":"Chen","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0590","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00004872-199611000-00011","article-title":"A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone","volume":"14","author":"Chen","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0595","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/FJC.0b013e31824fc5e3","article-title":"Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor rather than AT2 receptor of PPAR\u03b3 activation","volume":"59","author":"Chen","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0600","first-page":"332","article-title":"Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression","volume":"17","author":"Chen","year":"2011","journal-title":"Mol Vis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0605","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1582-4934.2009.00890.x","article-title":"Increasd rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels","volume":"14","author":"Chen","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0610","first-page":"540","article-title":"Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats","volume":"88","author":"Chen","year":"2008","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0615","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/jpet.108.142703","volume":"327","author":"Cheng","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0620","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1111\/j.1476-5381.2012.01832.x","article-title":"Renin activates PI3K-Akt-eNOS signaling through the AT1 receptor and mas receptor to modulate central blood pressure control in the nucleus tractus solitarii","volume":"166","author":"Cheng","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0625","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.1995.tb06653.x","article-title":"Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats","volume":"102","author":"Cheng","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0630","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db14-0779","article-title":"Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice","volume":"64","author":"Chin","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0635","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0006-291X(90)91575-D","article-title":"[3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype","volume":"172","author":"Chiu","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0640","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(25)19981-3","article-title":"Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent","volume":"252","author":"Chiu","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0645","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12272-009-1307-x","article-title":"Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats","volume":"32","author":"Choi","year":"2009","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0650","doi-asserted-by":"crossref","first-page":"e12274","DOI":"10.14814\/phy2.12274","article-title":"Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats","volume":"3","author":"Choisy","year":"2015","journal-title":"Physiol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0655","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(96)00823-0","article-title":"Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance","volume":"319","author":"Chow","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0660","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-2999(95)00282-P","article-title":"Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors","volume":"282","author":"Chow","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0665","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-3565(25)38613-1","article-title":"The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753\/MK954) in the dog","volume":"268","author":"Christ","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0670","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.83.4.1333","article-title":"Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II","volume":"83","author":"Christen","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0675","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(95)00237-F","article-title":"Effect of irbesartan (SR47436\/BMS186295) on angiotensin II-induced pressure responses in the pithed rat: Potential mechanisms of action","volume":"281","author":"Christophe","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0680","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0167-4889(93)90010-M","article-title":"Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells","volume":"1178","author":"Chua","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0685","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ndt\/gfp472","article-title":"Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats","volume":"25","author":"Chung","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0690","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2007.09.013","article-title":"Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells","volume":"198","author":"Cianchetti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0695","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/CH-2011-1394","article-title":"Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-\u03b1","volume":"48","author":"Cicha","year":"2011","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0700","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1006\/jmcc.1998.0796","article-title":"Angiotensin AT1 receptor inhibition in pacing induced heart failure: Effects on left ventricular myocardial collagen content and composition","volume":"30","author":"Clair","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0705","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1071-9164(98)90237-8","article-title":"AT1 angiotensin II receptor inhibition in pacing-induced heart failure: Effects on left ventricular performance and regional blood flow patterns","volume":"4","author":"Clair","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0710","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0022-3565(24)39307-3","article-title":"Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure","volume":"293","author":"Clair","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0715","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","article-title":"PPAR\u03b3-activating angiotensin type-1 receptor blockers induce adiponectin","volume":"46","author":"Clasen","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0720","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2337\/db07-0839","article-title":"Liver-specific peroxisome proliferator-activated receptor \u03b1 target gene regulation by the angiotensin type 1 receptor blocker telmisartan","volume":"57","author":"Clemenz","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0725","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0022-3565(25)20506-7","article-title":"Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD123177 and DuP 753 on proximal nephron and renal transport","volume":"259","author":"Cogan","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0730","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/HYPERTENSIONAHA.109.148049","article-title":"Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice","volume":"55","author":"Cole","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0735","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0196-9781(94)00150-5","article-title":"Kidney angiotensin II receptors and converting enzyme in neonatal and adult Wistar-Kyoto and spontaneously hypertensive rats","volume":"16","author":"Correa","year":"1995","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0740","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature04479","article-title":"Endothelial cells and VEGF in vascular development","volume":"438","author":"Coultas","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0745","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.RES.74.4.727","article-title":"Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat","volume":"74","author":"Crawford","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0750","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/FJC.0b013e31824e5273","article-title":"Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in syrian cardiomyopathic hamsters","volume":"59","author":"Crespo","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0755","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","article-title":"Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype","volume":"110","author":"Criscione","year":"1993","journal-title":"Br J Pharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2016.03.019_bb0760","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.jhh.1001442","article-title":"The renin\u2013angiotensin system in the brain: Possible therapeutic implications for AT1-receptor blockers","volume":"16","author":"Culman","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0765","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-2999(98)00983-2","article-title":"Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats","volume":"367","author":"Culman","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0770","first-page":"F515","article-title":"Angiotensin II conditions the slow component of autoregulation of renal blood flow","volume":"264","author":"Cupples","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0775","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/iep.12020","article-title":"Inhibition of glutaminyl cyclases alleviates CCl2-mediated inflammation of non-alcoholic fatty liver disease in mice","volume":"94","author":"Cynis","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0780","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1161\/01.STR.30.11.2391","article-title":"Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats","volume":"30","author":"Dai","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0785","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.bjp.0707454","article-title":"Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats","volume":"152","author":"Dai","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0790","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.103.17.2195","article-title":"Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure","volume":"103","author":"dalla Libera","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0795","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","article-title":"Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population","volume":"20","author":"Dang","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0800","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0167-0115(95)00085-P","article-title":"Binding of valsartan to mammalian angiotensin AT1 receptors","volume":"59","author":"de Gasparo","year":"1995","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0805","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International Union of Pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0810","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.HYP.34.4.969","article-title":"AT1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits","volume":"34","author":"de las Heras","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0815","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/01.hjh.0000358836.64052.43","article-title":"The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance","volume":"27","author":"de las Heras","year":"2009","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0820","first-page":"253","article-title":"Angiotensin II receptor subtypes in rat renal preglomerular vessels","volume":"2","author":"De Leon","year":"1992","journal-title":"Receptor"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0825","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00005344-199210000-00019","article-title":"The role of the renin\u2013angiotensin system in the control of cell communication in the heart: Effects of enalapril and angiotensin II","volume":"20","author":"De Mello","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0830","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.HYP.19.6.790","article-title":"Angiotensin II and renal functional reserve in rats with Goldblatt hypertension","volume":"19","author":"De Nicola","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0835","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0022-3565(25)10302-9","article-title":"Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in nonhuman primates","volume":"264","author":"DeGraaf","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0840","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.06.012","article-title":"Long-term amelioration of telmisartan on metabolic syndrome-related molecules in stroke-resistant spontaneously hypertensive rat after transient middle cerebral artery occlusion","volume":"23","author":"Deguchi","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0845","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.25.1.14","article-title":"Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers","volume":"25","author":"Delacretaz","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0850","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0922-4106(93)90071-G","article-title":"Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436","volume":"247","author":"Delisee","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0855","first-page":"H181","article-title":"Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat","volume":"300","author":"DeMarco","year":"2011","journal-title":"Am J Physiol"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb0860","first-page":"S208","article-title":"Nitric oxide participates in the renal vasodilatory effect of candesartan in anesthetized rats","volume":"10","author":"Demeilliers","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0865","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00004872-200206000-00027","article-title":"Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat","volume":"20","author":"Dendorfer","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0870","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncprheum0115","article-title":"Mechanisms and consequences of fibrosis in systemic sclerosis","volume":"2","author":"Denton","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0875","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/01.HYP.19.6.668","article-title":"Central DuP 753 does not lower blood pressure in spontaneously hypertensive rats","volume":"19","author":"DePasquale","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0880","doi-asserted-by":"crossref","first-page":"972761","DOI":"10.1155\/2014\/972761","article-title":"Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker Diabetic Fatty rats with metabolic syndrome","volume":"2014","author":"Di Filippo","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0885","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00210-011-0695-x","article-title":"Losartan exerts no protective effect against acute pulmonary embolism-induced hemodynamic changes","volume":"385","author":"Dias-Junior","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0890","first-page":"H636","article-title":"Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure","volume":"274","author":"DiBona","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0895","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1476-5381.1994.tb16191.x","article-title":"BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174","volume":"113","author":"Dickinson","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0900","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00004872-200405000-00005","article-title":"Angiotensin II and the hypertensive heart: A role for the AT2 receptor?","volume":"22","author":"Diez","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0905","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00005344-200109000-00008","article-title":"Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice","volume":"38","author":"Dol","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0910","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2353\/ajpath.2009.080652","article-title":"Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R","volume":"174","author":"Doller","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0915","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/jpet.111.182576","article-title":"Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats","volume":"339","author":"Dong","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0920","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/HJH.0b013e328338bb11","article-title":"Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice","volume":"28","author":"Dong","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0925","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s003950050144","article-title":"Attenuation of myocardial stunning by the AT1 receptor antagonist candesartan","volume":"94","author":"D\u00f6rge","year":"1999","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0930","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ajh\/5.5.276","article-title":"Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor","volume":"5","author":"Dostal","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0935","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/02841850902995544","article-title":"The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model","volume":"50","author":"Duan","year":"2009","journal-title":"Acta Radiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0940","first-page":"2067","article-title":"Angiotensin II and insulin induce growth of ciliary artery smooth muscle: Effects of AT1\/AT2 antagonists","volume":"39","author":"Dubey","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0945","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/01.hjh.0000166848.95592.a5","article-title":"Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrobascular structure in spontaneously hypertensive rats","volume":"23","author":"Dupuis","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0950","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/HJH.0b013e328339f1f3","article-title":"Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensi-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontanenously hypertensive rat","volume":"28","author":"Dupuis","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0955","doi-asserted-by":"crossref","first-page":"841343","DOI":"10.1155\/2010\/841343","article-title":"The effect of chronic candesaftan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat","volume":"2010","author":"Ecelbarger","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0960","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0022-3565(25)38416-8","article-title":"Angiotensin II inhibits glomerular adenylate cyclase via the angiotensin II receptor subtype 1 (AT1)","volume":"266","author":"Edwards","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0965","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0022-3565(25)11212-3","article-title":"Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566","volume":"260","author":"Edwards","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0970","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-3565(24)34865-7","article-title":"Transport of [3H]losartan across isolated perfused rabbit proximal tubule","volume":"290","author":"Edwards","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0975","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0022-3565(25)11466-3","article-title":"Characterization of renal angiotensin II receptors using subtype selective antagonists","volume":"260","author":"Edwards","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0980","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-3565(25)12239-8","article-title":"Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes","volume":"276","author":"Edwards","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0985","first-page":"F195","article-title":"Stimulation of basolateral Na+-HCO3-cotransporter by angiotensin II in rabbit renal cortex","volume":"265","author":"Eiam-Ong","year":"2015","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0990","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00005344-199308000-00010","article-title":"Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs","volume":"22","author":"El Amrani","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb0995","first-page":"F874","article-title":"Upregulation of renin\u2013angiotensin system and downregulation of kallikrein in obstructive nephropathy","volume":"264","author":"El-Dahr","year":"1993","journal-title":"Am J Physiol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb1000","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1007\/s00592-009-0156-x","article-title":"The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus","volume":"47","author":"Emre","year":"2010","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1005","first-page":"S205","article-title":"Function of angiotensin II type 2 receptor in the postglomerular efferent arteriole","volume":"63","author":"Endo","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000025613","article-title":"Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats","volume":"35","author":"Endo","year":"1998","journal-title":"J Vasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/HYPERTENSIONAHA.110.169193","article-title":"Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo. Implications for vascular regeneration","volume":"58","author":"Endtmann","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.vph.2006.05.002","article-title":"Molecular activation of PPAR\u03b3 by angiotensin II type 1-receptor antagonists","volume":"45","author":"Erbe","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00210-006-0080-3","article-title":"Metabolic effects of antihypertensive agents: Role of sympathoadrenal and renin\u2013angiotensin systems","volume":"373","author":"Ernsberger","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1030","first-page":"F411","article-title":"Angiotensin II receptor subtypes in cultured rat renal mesangial cells","volume":"263","author":"Ernsberger","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1035","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/ndt\/gfh499","article-title":"Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK\/Ta mice","volume":"19","author":"Fan","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phymed.2010.06.002","article-title":"Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension","volume":"18","author":"Fang","year":"2010","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1045","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.RES.72.6.1202","article-title":"Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation","volume":"72","author":"Farhy","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0006-291X(05)80142-1","article-title":"Kinins mediate the antiproliferative effect of ramipril in rat carotid artery","volume":"182","author":"Farhy","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neurobiolaging.2007.07.015","article-title":"Blood\u2013brain-barrier: Ageing and microvascular disease: Systematic review and meta-analysis","volume":"30","author":"Farrall","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1469-7793.2001.00533.x","article-title":"Impact of the renin\u2013angiotensin system on cerebral perfusion following subarachnoidal haemorrhage in the rat","volume":"535","author":"Fassot","year":"2001","journal-title":"J Physiol Lond"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1065","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1582-4934.2010.01085.x","article-title":"Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-\u03b4\/AMPK pathway","volume":"15","author":"Feng","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1070","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/mol.105.011601","article-title":"Single mutations at Asn295 and Leu305 in the cytoplasmic half of transmembrane \u03b1-helix domain 7 of the AT1 receptor induce promiscuous agonist specificity for angiotensin II fragments: A pseudo-constitutive activity","volume":"68","author":"Feng","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0922-4106(93)90170-E","article-title":"Angiotensin AT1 receptors mediate a positive inotropic effect of angiotensin II in guinea pig atria","volume":"245","author":"Feolde","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1080","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1006\/jmcc.1993.1148","article-title":"Angiotensin II receptor subtypes and biological responses in the rat heart","volume":"25","author":"Feolde","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1085","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/pr.113.008300","article-title":"Interaction of risk factors, comorbidities, and comedications with ischemia\/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning","volume":"66","author":"Ferdinandy","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/cs0960261","article-title":"Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels","volume":"96","author":"Ferri","year":"1999","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1095","first-page":"H250","article-title":"Angiotensin II receptor antagonism in ovine heart failure: Acute hemodynamic, hormonal, and renal effects","volume":"263","author":"Fitzpatrick","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0922-4106(95)90121-3","article-title":"Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells","volume":"289","author":"Flesch","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1681\/ASN.V10121","article-title":"Pressure natriuresis in nitric oxide-deficient hypertensive rats: Effect of antihypertensive treatments","volume":"10","author":"Fortepiani","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.HYP.34.1.138","article-title":"Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats","volume":"34","author":"Fortuno","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1475-2840-9-64","article-title":"PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice","volume":"9","author":"Foryst-Ludwig","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lfs.2011.04.019","article-title":"Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice","volume":"89","author":"Fouad","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000269779","article-title":"Nephroprotective effect of telmisartan in rats with ischemia\/reperfusion renal injury","volume":"85","author":"Fouad","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1130","doi-asserted-by":"crossref","first-page":"e42469","DOI":"10.1371\/journal.pone.0042469","article-title":"Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR","volume":"7","author":"Foulquier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1135","doi-asserted-by":"crossref","first-page":"e110766","DOI":"10.1371\/journal.pone.0110766","article-title":"Impact of short-term treatment with telmisartan on cerebral arterial remodeling in SHR","volume":"9","author":"Foulquier","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/jpet.108.144816","volume":"329","author":"Franklin","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2010.11.036","article-title":"Lack of evidence that nebivolol is a \u03b23-adrenoceptor agonist","volume":"654","author":"Frazier","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000139046","article-title":"Effect of chronic treatment with losartan potassium (DuP 753) on the elevation of blood pressure during chronic exposure of rats to cold","volume":"46","author":"Fregly","year":"1993","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FJC.0b013e31821dcbea","article-title":"The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expresion of plasminogen activator inhibitor type-I protein potential facilitating the stabilization of atherosclerotic plaques","volume":"58","author":"French","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1160","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jnutbio.2013.07.002","article-title":"Teh renin\u2013angiotensin system in adipose tissue and its metabolic consequences during obesity","volume":"24","author":"Frigolet","year":"2013","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1165","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1211\/0022357001774994","article-title":"Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man","volume":"52","author":"Fuchs","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2170\/jjphysiol.48.215","article-title":"Hypotensive effects of an angiotensin II type 1 receptor antagonist differ between exercised and sedentary rats aged from 4 to 19weeks","volume":"48","author":"Fujii","year":"1998","journal-title":"Jpn J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.febslet.2004.09.027","article-title":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes","volume":"576","author":"Fujimoto","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0024-3205(94)00678-4","article-title":"Effect of angiotensin II type 1 receptor antagonist on urinary prostaglandin E2 excretion following furosemide in rats","volume":"55","author":"Fujimura","year":"1994","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1185","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/en.2010-1312","article-title":"Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice","volume":"152","author":"Fujisaka","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/hr.2011.176","article-title":"Modulation of renal superoxide dismutase by telmisartan therapy in C57BL\/6-Ins2Akita diabetic mice","volume":"35","author":"Fujita","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1195","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1291\/hypres.20.263","article-title":"Chronic angiotensin blockade with candesartan cilexetil in DOCA\/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure","volume":"20","author":"Fujita","year":"1997","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1200","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1111\/j.1440-1681.1995.tb02858.x","article-title":"Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats","volume":"22","author":"Fujita","year":"1995","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mvr.2013.04.006","article-title":"Telmisartan, an angiotensin II receptor blocker, inhibits AGE-induced podocyte damage and detachment","volume":"88","author":"Fukami","year":"2013","journal-title":"Microvasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1210","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1016\/S0021-9258(19)50246-0","article-title":"Chimeric renin\u2013angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes","volume":"268","author":"Fukamizu","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.biopha.2010.09.014","article-title":"The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice","volume":"64","author":"Fukuda","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1220","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/01.ATV.19.5.1210","article-title":"Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats","volume":"19","author":"Fukuda","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-200103001-00007","article-title":"The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo","volume":"19","author":"Fukuhara","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1230","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.052","article-title":"Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in stroke-resistant spontaneously hypertensive rats","volume":"23","author":"Fukui","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0304-3940(96)12842-1","article-title":"Angiotensin II as a stimulator of Na+-dependent Ca2+ efflux from freshly isolated adult rat cardiomyocytes","volume":"213","author":"Fukuta","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1240","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/01.CIR.93.2.333","article-title":"Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril","volume":"93","author":"Furukawa","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1245","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejphar.2011.04.008","article-title":"Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor \u03b3 in 3T3-L1 adipocytes","volume":"660","author":"Furukawa","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000028308","article-title":"Effects of eprosartan on glomerular injury in rats with reduced renal mass","volume":"59","author":"Gandhi","year":"1999","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2012.02.002","article-title":"Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats","volume":"46","author":"Gandhi","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1260","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000355429","article-title":"Downregulation of microRNA-19b contributes to angiotensin II-induced overexpression of connective tissue growth factor in cardiomyocytes","volume":"127","author":"Gao","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.peptides.2014.03.014","article-title":"Comparison of secretagogue effects of rosiglitazone and telmisartan on ANP secretion in rats","volume":"56","author":"Gao","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1270","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1093\/ndt\/gfq245","article-title":"Treatment of db\/db diabetic mice with triptolide: A novel therapy for diabetic nephropathy","volume":"25","author":"Gao","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1275","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0024-3205(95)00069-0","article-title":"Short-term exposure to lipopolysaccharide is associated with microvascular contractile dysfunction in vivo","volume":"56","author":"Gao","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000054204","article-title":"Differential effects of enalapril and irbesartan in experimental papillary necrosis","volume":"24","author":"Garber","year":"2001","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1285","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.bjp.0702722","article-title":"Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries","volume":"127","author":"Garcha","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1290","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1677\/joe.0.1540133","article-title":"Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver","volume":"154","author":"Garcia-Sainz","year":"1997","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1295","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/01.HYP.24.5.531","article-title":"Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study","volume":"24","author":"Gasc","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1300","first-page":"207","article-title":"Characterization of glomerular angiotensin II receptor subtypes","volume":"2","author":"Gauquelin","year":"1992","journal-title":"Receptor"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1139\/Y08-028","article-title":"Role of the renin\u2013angiotensin\u2013aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure","volume":"86","author":"Ge","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb1310","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1161\/CIRCULATIONAHA.111.082610","article-title":"Modulation of transforming grwoth factor-\u03b2 signaling and extracellular matrix production in myoxomatous mitral valves by angiotensin II receptor blockers","volume":"126","author":"Geirsson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1315","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-3565(25)39445-0","article-title":"Mechanism of ochratoxin A-induced reduction of glomerular filtration in rats","volume":"267","author":"Gekle","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1320","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00005344-200009000-00008","article-title":"Effects of angiotensin II AT1-receptor blockade on coronary dynamics, function, and structure in postischemic heart failure in rats","volume":"36","author":"Gervais","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1325","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1472-8206.1999.tb00374.x","article-title":"Valsartan and coronary haemodynamics in early post-myocardial infarction in rats","volume":"13","author":"Gervais","year":"1999","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","article-title":"Candesartan","volume":"22","author":"Gleiter","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1335","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00210-002-0545-y","article-title":"Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats","volume":"365","author":"Gohlke","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3565(24)29352-6","article-title":"AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats","volume":"298","author":"Gohlke","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1345","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0022-3565(25)23835-6","article-title":"The of course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects","volume":"271","author":"Gorbea-Oppliger","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1350","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/AC.67.2.2154211","article-title":"Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy","volume":"67","author":"Goyal","year":"2012","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1463-1326.2011.01377.x","article-title":"Telmisartan, a dual ARB\/partial PPAR-\u03b3 agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes","volume":"13","author":"Goyal","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1360","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12012-011-9108-0","article-title":"Valsartan, an angiotensin ii receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity","volume":"11","author":"Goyal","year":"2011","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1365","first-page":"106","article-title":"Beneficial effect of combination of metformin and telmisartan on high fat diet-induced obesity in Wistar rats","volume":"4","author":"Goyal","year":"2011","journal-title":"Asian J Pharm Clin Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1370","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cbi.2010.03.030","article-title":"Modulation of PPAR-\u03b2 by telmisartan protects the heart against myocardial infarction in experimental diabetes","volume":"185","author":"Goyal","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2009.07.026","article-title":"Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction","volume":"619","author":"Goyal","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1380","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11010-008-9772-y","article-title":"Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats","volume":"314","author":"Goyal","year":"2008","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1385","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(11)70611-9","article-title":"Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats","volume":"63","author":"Goyal","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-5793(96)01371-3","article-title":"Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells","volume":"2400","author":"Graf","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1395","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1400","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/157340212803530394","article-title":"A systematic review of ransomized controlled trials examining the nephroprotective properties of antihypertensive medications","volume":"8","author":"Griffin","year":"2012","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1405","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00395-002-0356-9","article-title":"Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis","volume":"97","author":"Gross","year":"2002","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/01.HYP.26.3.471","article-title":"Effect of captopril and angiotensin II receptor blockade on pressure natriuresis in transgenic TGR(mRen-2)27 rats","volume":"26","author":"Gross","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1415","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00004872-200405000-00023","article-title":"Cardiac hypertrophy and fibrosis in chronic l-NAME-treated AT2 receptor-deficient mice","volume":"22","author":"Gross","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1420","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1097\/00004872-200311000-00028","article-title":"Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats","volume":"21","author":"Groth","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2005.01.045","article-title":"Combined effects of HMG-CoA-reductase inhibition and renin\u2013angiotensin system blockade on experimental atherosclerosis","volume":"182","author":"Grothusen","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1430","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.physbeh.2009.02.029","article-title":"Strain-dependent differences of restraint stress-induced hypertension in WKY and SHR","volume":"97","author":"Grundt","year":"2009","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1435","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/aps.2010.231","article-title":"Telmisartan attenuates isoproterenol-induced cardiac remodeling in rats via regulation of cardiac adiponectin expression","volume":"32","author":"Gu","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1440","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MAJ.0b013e3182112baf","article-title":"Endoplasmic reticulum stress caused by left ventricular hypertrophy in rats: Effects of telmisartan","volume":"342","author":"Guan","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1445","first-page":"509","article-title":"Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors","volume":"363","author":"Guimaraes","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00210-010-0544-3","article-title":"Losartan reduces mortality in a genetic model of heart failure","volume":"382","author":"G\u00fcnther","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1455","first-page":"2429","article-title":"Protective effects of telmisartan in a rat model of pulmonary arterial hypertension","volume":"20","author":"Guo","year":"2014","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1460","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11596-008-0306-3","article-title":"Effect of ARB on expression of CD68 and MCP-1 in adipose tissue of rats on long-term high fat diet","volume":"28","author":"Guo","year":"2008","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1465","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.2042-7158.2010.01157.x","article-title":"Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats","volume":"63","author":"Guo","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1470","first-page":"H1053","article-title":"Angiotensin II inhibition of L-type Ca2+ current in sinoatrial node cells of rabbits","volume":"268","author":"Habuchi","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1475","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1152\/physrev.1990.70.4.1067","article-title":"Morphology, physiology, and molecular biology of renin secretion","volume":"70","author":"Hackenthal","year":"1990","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2261-12-63","article-title":"Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response","volume":"12","author":"Hadi","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1485","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1152\/physrev.1991.71.3.617","article-title":"Reflexes from the heart","volume":"71","author":"Hainsworth","year":"1991","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1490","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0022-3565(25)39435-8","article-title":"Beta adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT1 receptor antagonist losartan","volume":"267","author":"Hajj-Ali","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb1495","first-page":"S75","article-title":"Intracellular actions of angiotensin II in vascular smooth muscle cells","volume":"10","author":"Haller","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1500","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1681\/ASN.V75687","article-title":"Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney","volume":"7","author":"Hamaguchi","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1505","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000331704","article-title":"Attenuation of immune-mediated renal injury by telmisartan, an angiotensin receptor blocker and a selective PPAR-\u03b3 activator","volume":"1","author":"Hamano","year":"2011","journal-title":"Nephron Extra"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb1510","first-page":"S234","article-title":"Coinhibition of immune and renin\u2013angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney","volume":"10","author":"Hamar","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1515","first-page":"249","article-title":"Effect of telmisartan in experimentally induced diabetetes mellitus in rats","volume":"1","author":"Hamed","year":"2007","journal-title":"Int J Health Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1520","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/0022-2828(95)90013-6","article-title":"Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction","volume":"27","author":"Hanatani","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1254\/jjp.78.45","article-title":"Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats","volume":"78","author":"Hanatani","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1530","first-page":"198","article-title":"Role of cardiac nonmyocates in cyclic mechanical stretch-induced myocyte hypertrophy","volume":"12","author":"Hara","year":"1997","journal-title":"Heart Vessels Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1535","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.97.4.315","article-title":"Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias","volume":"97","author":"Harada","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1540","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1023\/A:1007827720807","article-title":"Cilnidipine improves insulin sensitivity in the Otsuka Long\u2013Evans Tokushima fatty rat, a model of spontaneous NIDDM","volume":"13","author":"Harada","year":"1999","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb1545","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/00005344-199800001-00100","article-title":"Interaction of myoytes and nonmyocytes is necessary for mechanical stretch to induced ANP\/BNP productin in cardiocyte culture","volume":"31","author":"Harada","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1550","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trsl.2009.06.004","article-title":"AT1 receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats","volume":"154","author":"Harada","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1555","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2009.08.043","article-title":"Cerebroprotective action of telmisartan by inhibition of macrophages\/microglia expressing HMGB1 via peroxisom proliferator-activated receptor \u03b3-dependent mechanism","volume":"464","author":"Haraguchi","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1560","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(93)90958-K","article-title":"Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition","volume":"234","author":"Hartman","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1565","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/hr.2014.51","article-title":"Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: A role for inverse agonism of the angiotensin II type 1 receptor in obesity","volume":"37","author":"Hasan","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1570","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2009.01.001","article-title":"Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male spontaneously diabetic Torii rats","volume":"605","author":"Hasegawa","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1575","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/cs0960387","article-title":"Serial changes in sarcoplasmic reticulum gene expression in volume-overloaded cardiac hypertrophy in the rat: Effect of an angiotensin II receptor antagonist","volume":"96","author":"Hashida","year":"1999","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1580","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00005344-199702000-00019","article-title":"The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist","volume":"29","author":"Hashimoto","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1585","first-page":"767","article-title":"Effect of renin inhibition on adipokines in diabetic rats","volume":"27","author":"Hassanin","year":"2014","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1590","first-page":"625","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: Improvement of heart failure of rats with myocardial infarction by valsartan","volume":"47","author":"Hayashi","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1595","first-page":"F881","article-title":"Segmental differences in angiotensin receptor subtypes in interlobular artery of hydronephrotic rat kidneys","volume":"265","author":"Hayashi","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1600","first-page":"620","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: Hemodynamic effects of valsartan in rats and dogs","volume":"47","author":"Hayashi","year":"1997","journal-title":"Arzneim.-Forsch."},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1605","first-page":"79","article-title":"Effects of CV-11974 on renal haemodynamics and renal function in dogs","volume":"5","author":"He","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1610","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/HYPERTENSIONAHA.109.143958","article-title":"Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-\u03b4-dependent pathways","volume":"55","author":"He","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1615","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1620","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1073\/pnas.94.12.6391","article-title":"Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block","volume":"94","author":"Hein","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1625","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.1999.00496.x","article-title":"Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow","volume":"13","author":"Heinemann","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2680.1998.1810039.x","article-title":"Differential regulation of mesenteric and femoral blood flow in the rat as revealed by computerized data acquisition and evaluation","volume":"18","author":"Heinemann","year":"1998","journal-title":"J Auton Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2008.09.041","article-title":"S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells","volume":"600","author":"Hendriks-Balk","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1640","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(94)90394-8","article-title":"Effect of SR 47346, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro","volume":"251","author":"Herbert","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1645","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/HYPERTENSIONAHA.112.203679","article-title":"Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein","volume":"61","author":"Herrera","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1650","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/hr.2011.136","article-title":"Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice","volume":"35","author":"Higashikuni","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1655","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0895-7061(99)00174-0","article-title":"The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats","volume":"13","author":"Higashiura","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1660","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(99)00662-7","article-title":"The angiotensin AT1 receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling","volume":"384","author":"Hines","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1665","first-page":"84","article-title":"Effect of an AT1 receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocate hypertrophy in vitro","volume":"5","author":"Hirata","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1670","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000158979","article-title":"Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro","volume":"30","author":"Holycross","year":"1993","journal-title":"J Vasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1675","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2008.12.036","article-title":"Telmisartan induces proliferation of human endothelial progenitor cells via PPAR\u03b3-dependent PI3K\/Akt pathway","volume":"205","author":"Honda","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1680","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1050-1738(97)00029-7","article-title":"Animal models of heart failure. Recent developments and perspectives","volume":"7","author":"Hongo","year":"1997","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1685","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0895-7061(98)00203-9","article-title":"comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis","volume":"12","author":"Hope","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1690","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1476-5381.2010.01167.x","article-title":"Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage","volume":"163","author":"Horiuchi","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1695","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neuroscience.2005.03.054","article-title":"Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia","volume":"134","author":"Hosomi","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1700","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00210-014-1052-7","article-title":"Acute hemodynamic effects of angiotensin-converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution","volume":"387","author":"Hoyer","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1705","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/fcp.12057","article-title":"Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF\/Met system and PPAR\u03b3 pathway","volume":"28","author":"Hu","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1710","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00210-014-1024-y","article-title":"Fosinopril improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats","volume":"387","author":"Huang","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1715","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/HYPERTENSIONAHA.111.00160","article-title":"Hypoxia-inducible factor-1\u03b1 in vascular smooth muscle regulates blood pressure homeostasis through a peroxisome proliferator-activated receptor-\u03b3-angiotensin II receptor type 1 axis","volume":"62","author":"Huang","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1720","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1440-1681.2011.05486.x","article-title":"Renal (pro)renin contributes to development of diabetic kidney disease through transforming growth factor-\u03b21-connective tissue growth factor signalling cascade","volume":"38","author":"Huang","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1725","first-page":"342","article-title":"Effect of telmisartan and pridoxamine on oxidative stress in brain tissue of spontaneously hypertensive rats","volume":"28","author":"Huang","year":"2012","journal-title":"Chin J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1730","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1592\/phco.2005.25.11.1602","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus","volume":"25","author":"Hughes","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1735","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0895-7061(96)00177-X","article-title":"Vascular hypertrophy and albmumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade","volume":"9","author":"Hulthen","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1740","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10557-010-6274-4","article-title":"Blockade of the renin\u2013angiotensin system ameliorates apelin production in 3T3-L1 adipocytes","volume":"25","author":"Hung","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1745","doi-asserted-by":"crossref","first-page":"e26628","DOI":"10.1371\/journal.pone.0026628","article-title":"Transforming growth factor \u03b21 oppositely regulates the hypertrophic and contractile response to \u03b2-adrenergic stimulation in the heart","volume":"6","author":"Huntgeburth","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1750","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1043-2760(04)00213-9","article-title":"The role of the AT1 angiotensin receptor in cardiac hypertrophy: Angiotensin II receptor or stretch sensor?","volume":"15","author":"Hunyady","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1755","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1139\/Y11-012","article-title":"Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus","volume":"89","author":"Hussein","year":"2011","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1760","first-page":"F311","article-title":"Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis","volume":"263","author":"Hutchinson","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1765","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0014-2999(97)01542-2","article-title":"Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is medaited by the angiotensin AT1 receptor subtype","volume":"343","author":"Huwiler","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1770","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10557-014-6530-0","article-title":"Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat","volume":"28","author":"Hye Khan","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1775","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/ajh\/hpu016","article-title":"Azilsartan improves glycemic status and reduces kidney damage in Zucker diabetic fatty rats","volume":"27","author":"Hye Khan","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1780","first-page":"99","article-title":"Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl rats","volume":"5","author":"Ideishi","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1785","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yjmcc.2007.07.044","article-title":"Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis","volume":"43","author":"Ihara","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1790","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1046\/j.1523-1755.1999.00377.x","article-title":"Angiotensin II inhibits interleukin-1\u03b2-induced nitic oxide production in cultured rat mesangial cells","volume":"55","author":"Ihara","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1795","doi-asserted-by":"crossref","first-page":"e49642","DOI":"10.1371\/journal.pone.0049642","article-title":"Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms","volume":"7","author":"Iida","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1800","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0895-7061(94)00245-7","article-title":"Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives","volume":"8","author":"Iimura","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1805","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/HJH.0b013e3282f52c36","article-title":"Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-\u03b3-modulating activity, on nitric oxide bioavailability and atherosclerotic change","volume":"26","author":"Ikejima","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1810","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1291\/hypres.31.1199","article-title":"Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits","volume":"31","author":"Imanishi","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1815","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/HYPERTENSIONAHA.108.111120","article-title":"Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes","volume":"52","author":"Imanishi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1820","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/1479164110369848","article-title":"Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob\/ob mouse","volume":"7","author":"Imran","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1825","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/ajh.2011.6","article-title":"Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling","volume":"24","author":"Inaba","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1830","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/STROKEAHA.108.519801","article-title":"Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes","volume":"40","author":"Inaba","year":"2009","journal-title":"Stroke"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb1835","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1038\/sj.jhh.1000749","article-title":"Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-acting antihypertensive action","volume":"13","author":"Inada","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1840","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3109\/10641969709083206","article-title":"Protective effects of candesartan cilexetil (TCV-116) against stroke, kideny dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats","volume":"19","author":"Inada","year":"1997","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1845","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0022-3565(25)38647-7","volume":"268","author":"Inada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1850","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ki.1997.316","article-title":"Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats","volume":"52","author":"Inishi","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1855","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1055\/s-0030-1248304","article-title":"Measurement of adiponectin production from differentiated metabolic stem cells","volume":"42","author":"Inomata-Kurashiki","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1860","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/01.HYP.34.3.525","article-title":"Alternative angiotensin II formation in rat arteries occurs only at very high concentrations of angiotensin I","volume":"34","author":"Inoue","year":"1999","journal-title":"Hypertension"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb1865","first-page":"S178","article-title":"Candesartan cilextil protects against loss of autoregulatory efficiency in angiotensin II-infused rats","volume":"10","author":"Inscho","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1870","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1161\/01.CIR.100.22.2267","article-title":"Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: Effects of angiotensin receptor antagonism and converting enzyme inhibition","volume":"100","author":"Intengan","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1875","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature12000","article-title":"Conformational biosensors reveal GPCR signalling from endosomes","volume":"495","author":"Irannejad","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1880","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10641963.2014.897721","article-title":"Benefit of azilsartan on blood pressure elevation around the rest-to-active phase in spontaneously hypertensive rat","volume":"37","author":"Isegawa","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1885","first-page":"379","article-title":"Olmesartan blocks advanced glycation end products-induced VCAM-1 gene expression in mesangial cells by restoring angiotensin-convertnig enzyme 2 level","volume":"46","author":"Ishibashi","year":"2014","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1890","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1476-5381.1993.tb13497.x","article-title":"Pharmacological characteristics of the positive inotropic effect of angiotensin II in the rabbit ventricular myocardium","volume":"108","author":"Ishihata","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1895","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1536\/ihj.51.359","article-title":"Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ inuries in spontaneously hypertensive rats","volume":"51","author":"Ishimitsu","year":"2010","journal-title":"Int Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1900","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0922-4106(95)90084-5","article-title":"A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats","volume":"291","author":"Itazaki","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1905","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI116579","article-title":"Endothelin-1 is an autocrine\/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes","volume":"92","author":"Ito","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1910","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.108.188995","article-title":"Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload","volume":"104","author":"Ito","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1291\/hypres.18.69","article-title":"Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension","volume":"18","author":"Ito","year":"1995","journal-title":"Hypertens Res"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb1920","first-page":"S84","article-title":"AT1 calcium signaling in renal vascular smooth muscle cells","volume":"10","author":"Iversen","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1925","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjhyper.2006.12.010","article-title":"TAK-536, a new AT1 receptor blocker, improves glucose intolerance adipocyte differentiation","volume":"20","author":"Iwai","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1930","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1291\/hypres.31.161","article-title":"Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice","volume":"31","author":"Iwai","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1935","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.106.112755","article-title":"Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter","volume":"320","author":"Iwanaga","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1940","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/HJH.0b013e32833a551a","article-title":"Low dose telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-\u03b3 activation in diabetic mice","volume":"28","author":"Iwanami","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1945","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2014.49","article-title":"Role of angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/mas axis in the hypotensive effect of azilsartan","volume":"37","author":"Iwanami","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1950","first-page":"E286","article-title":"Valsartan, independently of AT1 receptor or PPARgamma, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes","volume":"302","author":"Iwashita","year":"2012","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1955","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1681\/ASN.2005050522","article-title":"Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering","volume":"16","author":"Izuhara","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1960","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-3565(25)38196-6","article-title":"Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: Subtypes of angiotensin receptors involved","volume":"265","author":"Jaiswal","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1965","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0735-1097(98)00441-0","article-title":"Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs","volume":"32","author":"Jalowy","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1970","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eigth joint national committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1975","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.24.6.671","article-title":"Role of the renin\u2013angiotensin system in neointima formation after injury in rabbits","volume":"24","author":"Janiak","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1980","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.hjh.0000242405.68461.84","article-title":"Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-\u03b3 activation","volume":"24","author":"Janke","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1985","first-page":"143","article-title":"Combination therapy with telmisartan and oxacylcitriol suppresses the progression of murine adriamycin nephropathy","volume":"129","author":"Jeong","year":"2015","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1990","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5582\/bst.2011.v5.4.173","article-title":"Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-beta1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels","volume":"5","author":"Jiao","year":"2011","journal-title":"Biosci Trends"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb1995","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/1440-1681.12250","article-title":"Antihypertensive and anti-inflammatory actions of combined azilsartan and chlorthalidone in Dahl salt-sensitive rats on a high-fat, high-salt diet","volume":"41","author":"Jin","year":"2014","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2000","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jjp.75.259","article-title":"Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo","volume":"75","author":"Jin","year":"1997","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00004872-199816050-00013","article-title":"Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters","volume":"16","author":"Jin","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2010","first-page":"54","article-title":"Effects of telmisartan on vascular ACE2 expression and oxidative stress levels on spontaneously hypertensive rats","volume":"28","author":"Jin","year":"2012","journal-title":"Chin Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.yjmcc.2004.08.004","article-title":"Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade","volume":"37","author":"Jones","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2020","doi-asserted-by":"crossref","first-page":"543062","DOI":"10.1155\/2012\/543062","article-title":"Influence of angiotensin II subtype 2 receptor (AT2R) antagonist, PD123319, on cardiovascular remodelling in aged spontaneously hypertensive rats during chronic angiotensin II subtype 1 receptor (AT1R) blockade","volume":"2012","author":"Jones","year":"2012","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2025","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1097\/00004872-199112006-00089","article-title":"Effect of the angiotensin antagonist DuP 753 on the renal adaptation to sodium restriction in the rat","volume":"9","author":"Jover","year":"1991","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2030","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/01.HYP.21.6.944","article-title":"Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade","volume":"21","author":"Jover","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2035","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/jpet.107.120097","article-title":"Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage","volume":"322","author":"Jung","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/0886022X.2015.1011967","article-title":"L-Arginine attenuates the ethylene glycol induced urolithiasis in ininephrectomized hypertensive rats: Role of KIM-1, NGAL, and NOs","volume":"37","author":"Kadhare","year":"2015","journal-title":"Ren Fail"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1440-1797.2008.00918.x","article-title":"Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells","volume":"13","author":"Kagawa","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2050","first-page":"89","article-title":"Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats","volume":"5","author":"Kagoshima","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1139\/cjpp-2012-0226","article-title":"Abnormal amounts of intracellular calcium regulatory proteins in SHRSP.Z-Leprfa\/IzmDmcr rats with metabolic syndrome and cardiac dysfunction","volume":"91","author":"Kagota","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vph.2014.06.005","article-title":"Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Leprfa\/IzmDmcr rats with metabolic syndrome","volume":"63","author":"Kagota","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/FJC.0b013e3181583d80","article-title":"Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR\/NDmcr-cp rats, spontaneously hypertensive obese rats","volume":"50","author":"Kagota","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2070","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1254\/jphs.08273FP","article-title":"Chronic production of peroxnitrite in the vascular wall impairs vasorelaxation function in SHR\/NDmcr-cp rats, an animal model of metabolic syndrome","volume":"109","author":"Kagota","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1139\/y11-029","article-title":"Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Leprfa\/IzmDmcr rats with metabolic syndrome","volume":"89","author":"Kagota","year":"2011","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2080","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/HJH.0b013e32834c46fd","article-title":"Molecular and cellular effects of azilsartan: A new generation angiotensin II receptor blocker","volume":"29","author":"Kajiya","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/jpet.113.211722","article-title":"Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor \u03b3 among clinically used angiotensin II receptor blockers: Drug-target interaction analyses","volume":"349","author":"Kakuta","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1291\/hypres.31.135","article-title":"Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats","volume":"31","author":"Kamari","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/HJH.0b013e3283325eee","article-title":"High-salt diet increases plasma adiponecting levels independent of blood pressure in hypertensive rats: The role of the renin\u2013angiotensin\u2013aldosterone system","volume":"28","author":"Kamari","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1254\/jjp.73.185","article-title":"Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats","volume":"73","author":"Kanagawa","year":"1997","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2105","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0022-3565(25)38259-5","article-title":"Losartan prevents salt-induced hypertension in reduced renal mass rats","volume":"265","author":"Kanagy","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2110","first-page":"67","article-title":"Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats","volume":"5","author":"Kanno","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.HYP.35.1.255","article-title":"Angiotensin II and PDGF-BB stimulate \u03b21-integrin-mediated adhesion and spreading in human VSMCs","volume":"35","author":"Kappert","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2120","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.109.132886","article-title":"Chronic traetment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPAR\u03b3 activation","volume":"54","author":"Kappert","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2125","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/HJH.0b013e328313e547","article-title":"Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation","volume":"26","author":"Kaschina","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1523-1755.1999.00643.x","article-title":"Renin\u2013angiotensin blockade lowers MCP-1 expression in diabetic rats","volume":"56","author":"Kato","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2135","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/0006-291X(92)90452-Q","article-title":"Hypotensive effect associated with a phospholipase C-\u03b41 gene mutation in the spontaneously hypertensive rat","volume":"187","author":"Katsuya","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2140","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/hr.2009.61","article-title":"Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats","volume":"32","author":"Kawai","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2145","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-3565(25)39478-4","article-title":"TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats","volume":"266","author":"Kawamura","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.HYP.35.1.273","article-title":"Angiotensin II enhances integrin and \u03b1-actinin expression in adult rat cardiac fibroblasts","volume":"35","author":"Kawano","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.101.10.1130","article-title":"Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts","volume":"101","author":"Kawano","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-3565(25)12909-1","article-title":"The angiotensin receptor antagonist 2-ethoxy-1-[[2\u2032-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglemerular feedback response during NO synthase blockade in rats","volume":"277","author":"Kawata","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0024-3205(98)00014-9","article-title":"Angiotensin, LDL peroxidation and atherosclerosis","volume":"63","author":"Keidar","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1006\/bbrc.1997.6844","article-title":"The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and ethreosclerosis in apolipoprotein E-deficient mice","volume":"236","author":"Keidar","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2175","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(25)10912-9","article-title":"Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands","volume":"262","author":"Keiser","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2180","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3565(25)24563-3","article-title":"Pharmacological characterization of CI-996, a new angiotensin receptor antagonist","volume":"272","author":"Keiser","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11010-009-0080-y","article-title":"Investigation of effects of lacidipine, ramipril and valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats","volume":"328","author":"Keles","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2190","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1523-1755.2000.00038.x","article-title":"Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat","volume":"57","author":"Kelly","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: Detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2200","first-page":"107","article-title":"Glomerular dimensions in spontaneously hypertensive rats: Effects of AT1 antagonism","volume":"14","author":"Kett","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ajh.2011.34","article-title":"Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome","volume":"24","author":"Khan","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2210","first-page":"397","article-title":"Possible cardio-protective effects of telmisartan against 5-fluoruracil-induced cadiotoxicity in Wister rats","volume":"6","author":"Khudhair","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1677\/JOE-06-0045","article-title":"A rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats","volume":"192","author":"Kikuchi","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2220","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbadis.2009.10.009","article-title":"Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice","volume":"1802","author":"Kikumoto","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2225","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00004872-199715066-00002","article-title":"Involvement of angiotensin II in cardiovascular and renal injury: Effects of an AT1-receptor antagonist on gene expression and the cellular phenotype","volume":"15","author":"Kim","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10157-011-0494-1","article-title":"Convergence of major physiological stimuli for renin release on the Gs\u03b1\/cyclic adenosine monophosphate signaling pathway","volume":"16","author":"Kim","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2235","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/01.CIR.92.1.88","article-title":"Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronecting in rat injured artery","volume":"92","author":"Kim","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2240","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/mol.113.091157","article-title":"Mechanism of erythropoietin regulation by angiotensin II","volume":"85","author":"Kim","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2245","first-page":"54","article-title":"Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats","volume":"5","author":"Kim","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2250","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/01.HYP.24.2.195","article-title":"Role of angiotensin II renal injury of deoxcorticosterone acetate-salt hypertensive rats","volume":"24","author":"Kim","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2255","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ki.1994.404","article-title":"Contribution of renal angiotensin II type 1 receptor to gene expressions in hypertension-induced renal injury","volume":"46","author":"Kim","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2260","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0022-3565(25)09620-X","article-title":"Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-\u03b21 and extracellular matrix in cardiac and vascular tissues of hypertensive rats","volume":"273","author":"Kim","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1291\/hypres.20.133","article-title":"Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats","volume":"20","author":"Kim","year":"1997","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2270","first-page":"E426","article-title":"Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts","volume":"269","author":"Kim","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00424-012-1170-3","article-title":"The angiotensin receptor blocker and PPAR-\u03b3 agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: Novel mechanism of drug action","volume":"464","author":"Kim","year":"2012","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2280","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.HYP.35.3.769","article-title":"Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats","volume":"35","author":"Kim","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2285","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bbrc.2014.10.077","article-title":"Telmisartan, a possible PPAR-\u03b4 agonist, reduces TNF-\u03b1-stimulated VEGF-C production by inhibiting the p38MAPK\/HSP27 pathway in human proximal tubular cells","volume":"454","author":"Kimura","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2290","first-page":"71","article-title":"Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal aterioles","volume":"5","author":"Kimura","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2295","first-page":"43","article-title":"Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury","volume":"5","author":"Kino","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2300","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1111\/j.1440-1681.1995.tb02954.x","article-title":"Effect of an angiotensin II receptor antagonist, TCV-116, on neointimal formation following balloon injury in the SHR carotid artery","volume":"22","author":"Kino","year":"1995","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2305","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(93)90153-9","article-title":"Effects of a nonpeptide angiotensin II receptor antagonist (CV-11794) on [Ca2+]i and cell motion in cultured ventricular myocytes","volume":"235","author":"Kinugawa","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2310","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/hr.2012.63","article-title":"Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT1 receptor in the rostral ventrolateral medulla of hypertensive rats","volume":"35","author":"Kishi","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2315","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajh\/hpt188","article-title":"Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure","volume":"27","author":"Kishi","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2320","first-page":"681","volume":"46","author":"Kito","year":"1996","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2325","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10641960903254430","article-title":"Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan","volume":"32","author":"Kiya","year":"2010","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","article-title":"Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis","volume":"47","author":"Klein","year":"2014","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.24.4.467","article-title":"Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats","volume":"24","author":"Kline","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2340","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00174868","article-title":"Positive chronotropic activity of angiotensin II in the pithed normotensive rat is primarily due to activation of cardiac \u03b21-adrenoceptors","volume":"338","author":"Knape","year":"1988","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2345","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/ATVBAHA.111.232058","article-title":"Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase. Beneficial effects of therapy with the AT1 receptor blocker telmisartan","volume":"31","author":"Knorr","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0006-2952(96)00691-0","article-title":"Angiotensin type-1 (AT1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells","volume":"53","author":"Ko","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0922-4106(92)90130-N","article-title":"Losartan inhibits the angiotensin II-induced stimulation of the phosphoinositide signalling system in vascular smooth muscle cells","volume":"227","author":"Ko","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2360","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1253\/circj.CJ-10-0892","article-title":"Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes","volume":"75","author":"Ko","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2365","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1089\/neu.2009.0965","article-title":"Angiotensin Ii type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A2 level in experimental stroke","volume":"26","author":"Kobayashi","year":"2009","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2370","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/01.HYP.21.6.1051","article-title":"Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats","volume":"21","author":"Kobayashi","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2375","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/ajh.2008.27","article-title":"Cardioprotective mechanism of telmisartan via PPAR-\u03b3-eNOS pathway in Dahl salt-sensitive hypertensive rats","volume":"21","author":"Kobayashi","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2380","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.RES.82.2.244","article-title":"Biphasic activation of the JAK\/STAT pathway by angiotensin II in rat cardiomyocytes","volume":"82","author":"Kodama","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00005344-199402000-00001","article-title":"Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells","volume":"23","author":"Koh","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2390","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/bph.12229","article-title":"Losartan protects liver against ischemia-reperfusion injury through PPAR\u03b3 activation andr eceptor for advanced glycation end-products down-regulation","volume":"169","author":"Koh","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2395","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm960547h","article-title":"Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres","volume":"39","author":"Kohara","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2400","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.HYP.21.6.975","article-title":"Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat","volume":"21","author":"Kohara","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2405","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.RES.76.5.892","article-title":"Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effects of angiotensin II blockade","volume":"76","author":"Kohya","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2410","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00004872-200106001-00002","article-title":"In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist","volume":"19","author":"Koike","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2415","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1161\/01.CIR.89.5.2204","article-title":"Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro","volume":"89","author":"Kojima","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2420","doi-asserted-by":"crossref","first-page":"e108994","DOI":"10.1371\/journal.pone.0108994","article-title":"Inhibition of kidney proximal tubular glucose reabsorption doesn ot prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice","volume":"9","author":"Komala","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2425","first-page":"F588","article-title":"Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: Role of kinins","volume":"268","author":"Komers","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2430","first-page":"613","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: Valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment","volume":"47","author":"Kometani","year":"1997","journal-title":"Arzneimittelforschung"},{"issue":"Suppl. C","key":"10.1016\/j.pharmthera.2016.03.019_bb2435","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurheartj\/16.suppl_C.8","article-title":"Protein kinase cascade activated by mechanical stress in cardiocytes: Possible involvement of angiotensin II","volume":"16","author":"Komuro","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2440","doi-asserted-by":"crossref","first-page":"e87848","DOI":"10.1371\/journal.pone.0087848","article-title":"KDT501, a dervative from hops, normalizes glucose metaboliswm and body weight in rodent models of diabetes","volume":"9","author":"Konda","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2445","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.09.037","article-title":"Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke","volume":"24","author":"Kono","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2450","doi-asserted-by":"crossref","first-page":"159874","DOI":"10.1155\/2012\/159874","article-title":"An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice","volume":"2012","author":"Koshizaka","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2455","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2353\/ajpath.2010.090578","article-title":"eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin\u2013angiotensin blockade than from aldosterone receptor antagonists","volume":"176","author":"Kosugi","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2460","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-013-0846-3","article-title":"Relaxation of human pulmonary arteries by PPAR\u03b3 agonists","volume":"386","author":"Kozlowska","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2465","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2015.02.004","article-title":"Ca2+ homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling","volume":"460","author":"Krebs","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2470","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/labinvest.2010.116","article-title":"Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice","volume":"90","author":"Krieger","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2475","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0008-6363(98)00050-9","article-title":"Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns","volume":"38","author":"Krombach","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2480","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00005344-199601000-00010","article-title":"Inhibitory effect of an angiotensin II type receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats","volume":"27","author":"Kubo","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2485","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/jm00064a011","article-title":"Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles","volume":"36","author":"Kubo","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2490","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1478-3231.2009.02006.x","article-title":"Telmisartan attenuates progression of steatohepatitis in mice: Role of hepatic macrophage infiltration and effects on adipose tissues","volume":"29","author":"Kudo","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2495","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.HYP.21.4.476","article-title":"Role of nitric oxide and angiotensin II in the regulation of sympathetic nerve activity in spontaneously hypertensive rats","volume":"21","author":"Kumagai","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2500","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.expneurol.2007.11.028","article-title":"Positive effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure","volume":"210","author":"Kumai","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2505","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/0886022X.2010.501936","article-title":"Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors","volume":"32","author":"Kumar","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2510","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/00004872-199012000-00004","article-title":"Genetic determination of heart and kidney weights studied using a set of recombinant inbred strains: The relationship to blood pressure","volume":"8","author":"Kunes","year":"1990","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2515","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.023","article-title":"Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat","volume":"23","author":"Kurata","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2520","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12975-013-0321-y","article-title":"Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO","volume":"6","author":"Kurata","year":"2014","journal-title":"Transl Stroke Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2525","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/db07-1281","article-title":"Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina","volume":"57","author":"Kurihara","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2530","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2015.01.037","article-title":"Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathway","volume":"239","author":"Kurokawa","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mrgentox.2013.04.013","article-title":"Telmisartan ameliorates germ cell toxicity in the STZ-induced diabetic rat: Studies on possible molecular mechanisms","volume":"755","author":"Kushwaha","year":"2013","journal-title":"Mutat Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2540","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2011.07.014","article-title":"Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models","volume":"669","author":"Kusumoto","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2545","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.111.176263","article-title":"Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-\u03b3\/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade","volume":"59","author":"Kusunoki","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2550","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00441-011-1132-7","article-title":"Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrogphage infiltration and fat accumulation","volume":"344","author":"Kuwashiro","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2555","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0014-2999(94)00484-6","article-title":"Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models","volume":"264","author":"Lacour","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2560","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/00004872-199311000-00005","article-title":"Pharmacological study of SR 47346, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys","volume":"11","author":"Lacour","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2565","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1172\/JCI115949","article-title":"Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass","volume":"90","author":"Lafayette","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2570","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10715762.2011.560149","article-title":"Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1\u20137) mas receptor expression associated with its PPAR-\u03b3 action","volume":"45","author":"Lakshmanan","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2575","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1139\/y98-002","article-title":"Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat","volume":"76","author":"Lambert","year":"1998","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2580","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/FJC.0b013e31802c2f77","article-title":"Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-\u03b5 expression in the mouse heart","volume":"49","author":"Lange","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2585","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.V75653","article-title":"Angiotensin II modulates glomerular capillary permselectivit in rat isolated perfused kidney","volume":"7","author":"Lapinski","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2590","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/HJH.0b013e3283314bc7","article-title":"Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes","volume":"27","author":"Larrayoz","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2595","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bjp.0703422","article-title":"Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet","volume":"130","author":"Lassila","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2600","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(00)00282-X","article-title":"Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats","volume":"398","author":"Lassila","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2605","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000353155","article-title":"The novel angiotensin II receptor blocker azilsartan medoxomil ameliorates insulin resistance induced by chronic angiotensin II treatment in rat skeletal muscle","volume":"3","author":"Lastra","year":"2013","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2610","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.ATV.21.1.61","article-title":"ACE inhibitor and AT1 antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through B2 receptor activation","volume":"21","author":"Lauth","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2615","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000025724","article-title":"Prevention of increases in blood pressure and left ventricular mass and remodeling of resistance arteries in young New Zealand genetically hypertensive rats: The effects of chronic treatment with valsartan, enalapril and felodipine","volume":"37","author":"Ledingham","year":"2000","journal-title":"J Vasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2620","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12272-010-0915-9","article-title":"Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats","volume":"33","author":"Lee","year":"2010","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2625","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.37.3.981","article-title":"Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade","volume":"37","author":"Leenen","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2630","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ajh\/5.9.648","article-title":"AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes","volume":"5","author":"Leung","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2635","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0022-3565(25)39603-5","article-title":"Characterization of angiotensin II receptors in smooth muscle preparations of the guinea pig in vitro","volume":"267","author":"Leung","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2640","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.26.6.989","article-title":"Regional hemodynamic effects of the AT1 receptor antagonist CV-11974 in conscious renal hypertensive rats","volume":"26","author":"Li","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2645","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/cs0910147","article-title":"Angiotensin type 1 antagonists CV-11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats","volume":"91","author":"Li","year":"1996","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2650","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11033-011-0703-8","article-title":"The therapeutic potential of G-CSF in pressure overload induced ventricular reconstruction and heart failure in mice","volume":"39","author":"Li","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2655","doi-asserted-by":"crossref","first-page":"618923","DOI":"10.1155\/2012\/618923","article-title":"Blockade of renin angiotensin system increased resistance to STZ-induced diabetes in rats with long-term high-fat diet","volume":"2012","author":"Li","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2660","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2143\/AC.65.1.2045885","article-title":"Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism","volume":"65","author":"Li","year":"2010","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2665","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","article-title":"Novel angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in canine coronary arteries and human platelet aggregation","volume":"292","author":"Li","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2670","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(98)00309-8","article-title":"Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits","volume":"143","author":"Li","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2675","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.HYP.0000145179.44166.0f","article-title":"Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis","volume":"44","author":"Li","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2680","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00210-006-0069-y","article-title":"Metabolic effects of telmisartan in spontaneously hypertensive rats","volume":"373","author":"Li","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2685","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11033-014-3757-6","article-title":"Telmisartan-induced PPAR\u03b3 activity attenuates lipid accumulation in VSMCs via induction of autophagy","volume":"42","author":"Li","year":"2015","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2690","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2169\/internalmedicine.50.5250","article-title":"Correlation of different NADPH oxidase homologues with late endothelial progenitor cell senescence induced by angiotensin II: Effect of telmisartan","volume":"50","author":"Li","year":"2011","journal-title":"Intern Med (Tokyo)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2695","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pupt.2013.11.003","article-title":"Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent P3IK\/Akt\/eNOS pathway","volume":"28","author":"Li","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2700","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/db12-0570","article-title":"Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-\u03b4 activation","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2705","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/STROKEAHA.107.503458","article-title":"Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density","volume":"39","author":"Li","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2710","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1472-8206.2001.00018.x","article-title":"Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries","volume":"15","author":"Li","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2715","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2133\/dmpk.23.263","article-title":"Effects of angiotensin II receptor blockers on renal handling or uric acid in rats","volume":"23","author":"Li","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2720","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjp.0706217","article-title":"Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II","volume":"145","author":"Li","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2725","doi-asserted-by":"crossref","first-page":"e90217","DOI":"10.1371\/journal.pone.0090217","article-title":"Angiotensin II receptor blockers improve peripheral endothelial function: A meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2730","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s11596-009-0602-6","article-title":"Effect of renin angiotensin system blockade on the islet microvessel density of diabetic rats and its relationship with islet function","volume":"29","author":"Li","year":"2009","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb2735","first-page":"18","article-title":"Reciprocal role of the AT1 receptor in modulating renal and neuronal AT1 mRNA expression","volume":"10","author":"Li","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2740","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/hr.2010.182","article-title":"Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice","volume":"33","author":"Li","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2745","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FJC.0b013e318169e948","article-title":"Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats","volume":"51","author":"Liang","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2750","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ndt\/gfq514","article-title":"Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats","volume":"26","author":"Liang","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2755","first-page":"189","article-title":"Effects of angiotensin on increased body weight and dyslipidemia induced by high-fat diet in rats","volume":"46","author":"Liang","year":"2011","journal-title":"Chin Pharm J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2760","first-page":"353","article-title":"Antagonism of the renin\u2013angiotensin system, hypertrophy and gene expression in cardiac myocytes","volume":"21","author":"Lijnen","year":"1999","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2765","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1358\/mf.2000.22.10.802287","article-title":"Induction of cardiac fibrosis by angiotensin II","volume":"22","author":"Lijnen","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2770","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3317\/jraas.2001.012","article-title":"Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors","volume":"2","author":"Lijnen","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2775","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1021\/jm00092a017","article-title":"Nonpeptide angiotensin II receptor antagonists: Synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1-yl]phenyl]methyl]imidazole derivatives and their in vitro activity","volume":"35","author":"Lin","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2780","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.HYP.19.5.428","article-title":"Genetic variation in hypertensive and \"control\" strains. What are we controlling for anyway?","volume":"19","author":"Lindpaintner","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2785","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/01.hjh.0000242415.73406.17","article-title":"Telmisartan inhibits \u03b22-integrin MAC-1 expression in human T-lymphocytes","volume":"24","author":"Link","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2790","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1097\/00004872-199112006-00184","article-title":"Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats","volume":"9","author":"Linz","year":"1991","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2795","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90892-L","article-title":"Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays","volume":"240","author":"Liu","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2800","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0090-6980(92)90070-A","article-title":"DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2\/prostaglandin H2 (TP) receptors","volume":"44","author":"Liu","year":"1992","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2805","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1476-5381.1992.tb14322.x","article-title":"Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action","volume":"106","author":"Liu","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2810","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0022-2828(95)90038-1","article-title":"Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts","volume":"27","author":"Liu","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2815","first-page":"1165","article-title":"Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats","volume":"16","author":"Liu","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2820","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13105-010-0039-1","article-title":"Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by antiogensin receptor blocker telmisartan - a proteomic analyis","volume":"66","author":"Liu","year":"2010","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2825","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/FJC.0b013e3182073e41","article-title":"Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats","volume":"57","author":"Liu","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2830","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1179\/1743132815Y.0000000002","article-title":"Protective effect of telmisartan on neurovascular unit and inflammasome in stroke-resistant spontaneously hypertensive rats","volume":"37","author":"Liu","year":"2015","journal-title":"Neurol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2835","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/HYPERTENSIONAHA.108.116947","article-title":"Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats","volume":"53","author":"Liu","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2840","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.115.223107","article-title":"A novel partial agonist of peroxisome proliferator-activated receptor \u03b2 with excellent effect on insulin resistance and type 2 diabetes","volume":"353","author":"Liu","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2845","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijcard.2009.09.540","article-title":"Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis","volume":"137","author":"Liu","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2850","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/00004872-199310000-00007","article-title":"Failure of the heat-shock protein 70 locus to cosegregate with blood pressure in spontaneously hypertensive rat x Wistar-Kyoto rat cross","volume":"11","author":"Lodwick","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2855","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/jsre.1999.5732","article-title":"Effects of angiotensin type-1 receptor blockade on pericardial fibrosis","volume":"87","author":"Loging","year":"1999","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2860","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1161\/01.ATV.18.9.1408","article-title":"Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: Prevention by angiotensin II antagonism","volume":"18","author":"Luvara","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2865","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00004872-199210120-00005","article-title":"Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor","volume":"10","author":"Lyall","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2870","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacc.2010.08.635","article-title":"Adrenal \u03b2-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels","volume":"57","author":"Lymperopoulos","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2875","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1073\/pnas.0811706106","article-title":"An adrenal \u03b2-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo","volume":"106","author":"Lymperopoulos","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2880","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.09.070","article-title":"Different potencies of angiotensin receptor blockers at suppressing adrenal \u03b2-arrestin1-dependent post-myocardiacl infarction hyperaldosteronism","volume":"64","author":"Lymperopoulos","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2885","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bone.2010.03.016","article-title":"Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats","volume":"47","author":"Ma","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2890","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0008-6363(99)00249-7","article-title":"Vasoconstriction by in situ formed angiotensin II: Role of ACE and chymase","volume":"44","author":"Maassen van den Brink","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2895","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2999(93)90665-5","article-title":"Renal actions of the selective angiotensin AT2 receptor ligands CGP 42212B and PD 123319 in the sodium-depleted rat","volume":"249","author":"Macari","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2900","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/cs0830549","article-title":"Effects of the angiotensin II receptor antagonist losartan (DuP 753\/MK 954) on arterial blood pressure, heart rate, plasma concentrations of angiotensin II and renin and the pressor response to infused angiotensin II in the salt-deplete dog","volume":"83","author":"MacFadyen","year":"1992","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2905","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/cs0850157","article-title":"Haemodynamic and hormonal responses to losartan (DuP753\/MK954) infusion during cardiac catheterization in conscious salt-deplete dogs","volume":"85","author":"MacFadyen","year":"1993","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2910","first-page":"S11","article-title":"TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation","volume":"12","author":"Mackenzie","year":"1994","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2915","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-199715066-00005","article-title":"Candesartan cilexetil reduces chronic renal allograft injury in Fischer \u2013>Lewis rats","volume":"15","author":"Mackenzie","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2920","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0167-0115(93)90238-4","article-title":"Signal transduction mediated by angiotensin II receptor subtypes expressed in rat renal mesangial cells","volume":"44","author":"Madhun","year":"1993","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2925","first-page":"H2139","article-title":"Chronic effects of ANG II antagonist in heart failure: Improvement of cGMP generation from ANP","volume":"272","author":"Maeda","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2930","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/labinvest.2011.45","article-title":"Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma","volume":"91","author":"Maejima","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2935","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1161\/01.CIR.96.9.3053","article-title":"Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: Acute effects of mixed ETA\/ETB and AT1 receptor antagonists in vivo and in vitro","volume":"96","author":"Magga","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2940","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0895-7061(99)00133-8","article-title":"Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay","volume":"12","author":"Maillard","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2945","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1124\/jpet.102.036772","article-title":"In vitro and in vivo characterization of the activity of telmisartan: An insurmountable angiotensin II receptor antagonist","volume":"302","author":"Maillard","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2950","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1124\/jpet.102.040956","article-title":"Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on \u03b2-adrenoceptor signaling in heart failure produced by myocardial infarction in rabbits: Reversal of altered expression of \u03b2-adrenoceptor kinase and Gi\u03b1","volume":"304","author":"Makino","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2955","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2125.1998.00722.x","article-title":"Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man","volume":"45","author":"Malerczyk","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2960","first-page":"727","article-title":"Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats","volume":"19","author":"Mandarim-de-Lacerda","year":"2004","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2965","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0149-2918(00)83062-3","article-title":"Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators","volume":"22","author":"Manolis","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2970","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2014.12.008","article-title":"Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis","volume":"748","author":"Maoik","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2975","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation. Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marcen","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4682-3-1","article-title":"Common angiotensin receptor blockers may driectly modulate the immune system via VDR, PPAR and CCR2b","volume":"3","author":"Marshall","year":"2006","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2985","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1139\/y95-058","article-title":"Inhibition by BMS 186295, a slective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo","volume":"73","author":"Martineau","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2990","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1463-1326.2006.00644.x","article-title":"The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus","volume":"9","author":"Mathur","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb2995","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.99.6.817","article-title":"Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia\/reoxygenation injury in cultured rat cardiac myocytes","volume":"99","author":"Matoba","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3000","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/147323000703500407","volume":"35","author":"Matsui","year":"2007","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3005","first-page":"R1611","article-title":"Angiotensin II acts at AT1 receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex","volume":"275","author":"Matsumara","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3010","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/hr.2010.184","article-title":"Impact of RGS2 deficiency on the therapeutic effect of telmisartan in angiotensin II-induced aortic aneurysm","volume":"33","author":"Matsumoto","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2840-13-30","article-title":"Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)\/Thre(497) of endothelial nitric oxide synthase in diabetic mice","volume":"13","author":"Matsumoto","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/ATVBAHA.110.222067","article-title":"Telmisartan exerts antiatherosclerotic effects by activating peroxsome proliferator-activated receptor-\u03b3 in macrophages","volume":"31","author":"Matsumura","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3025","first-page":"207","article-title":"Renoprotective effects of telmisartan after unilateral renal ablation in rats","volume":"6","author":"Matsuo","year":"2013","journal-title":"Int J Nephrol Renov Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-291X(05)80804-6","article-title":"Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor","volume":"186","author":"Mauzy","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/ki.1993.52","article-title":"Effects of angiotensin II receptor blockade on remnant glomerular permselectivity","volume":"43","author":"Mayer","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/01.HYP.33.3.850","article-title":"Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists","volume":"33","author":"Mazzolai","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3045","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1161\/01.HYP.35.4.985","article-title":"Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice","volume":"35","author":"Mazzolai","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3050","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1152\/jappl.1992.73.5.2054","article-title":"Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat","volume":"73","author":"McMahon","year":"1992","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3055","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10620-012-2499-3","article-title":"Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-\/- mouse model","volume":"58","author":"Mende","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.HYP.33.1.389","article-title":"Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension","volume":"33","author":"Mervaala","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3065","first-page":"555","article-title":"Local action of the renin angiotensin system in the porcine ophthalmic circulation: Effects of ACE-inhibitors and angiotensin receptor antagonists","volume":"36","author":"Meyer","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002018-200427050-00005","article-title":"Safety of telmisartan in patients with arterial hypertension. An open-label observational study","volume":"27","author":"Michel","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3075","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.HYP.19.4.365","article-title":"On the role of renal \u03b1-adrenergic receptors in spontaneously hypertensive rats","volume":"19","author":"Michel","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002100000363","article-title":"Mitogen-activated protein kinases in the heart","volume":"363","author":"Michel","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3090","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1111\/j.1476-5381.2011.01726.x","article-title":"Double blockade of angiotensin II (AT1)-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats","volume":"165","author":"Miesel","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2013.157","article-title":"Telmisartan activates endogenous peroxisome proliferator-activated receptor-\u03b4 and may have anti-fibrotic effects in human mesangial cells","volume":"37","author":"Mikami","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.CIR.102.4.458","article-title":"Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation","volume":"102","author":"Miki","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1432-1033.1992.tb16936.x","article-title":"Effects of angiotensins on cellular hypertrophy and c-fos expression in cultured arterial smooth muscle cells","volume":"206","author":"Millet","year":"1992","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3110","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/HYPERTENSIONAHA.112.192401","article-title":"Peroxisome proliferator-activated receptor-gamma activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood\u2013brain barrier impairment and cognitive decline in type 2 diabetic mice","volume":"59","author":"Min","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.fjc.0000180902.78230.fd","article-title":"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker","volume":"46","author":"Mire","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3120","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1248\/bpb.22.863","article-title":"Imidapril, and angiotensin-converting enzyme inhibitor, inhibits thrombosis via reduction in aortic plasminogen activator inhibitor type-1 levels in spontaneously hypertensive rats","volume":"22","author":"Mitsui","year":"1999","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3125","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1074\/jbc.M602144200","article-title":"Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor","volume":"281","author":"Miura","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Angiotensin II type 1 receptor blockers: Class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/me.2007-0312","article-title":"Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state","volume":"22","author":"Miura","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide","volume":"37","author":"Miura","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/hr.2012.147","article-title":"Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan","volume":"36","author":"Miura","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3150","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1291\/hypres.26.937","article-title":"Molecular analysis of the structure and function of the angiotensin II type 1 receptor","volume":"26","author":"Miura","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.neures.2008.03.003","article-title":"Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain","volume":"61","author":"Miyamoto","year":"2008","journal-title":"Neurosci Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1254\/jjp.79.455","article-title":"Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog","volume":"79","author":"Miyazaki","year":"1999","journal-title":"Jpn J Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb3165","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/sj.jhh.1000745","article-title":"Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury","volume":"13","author":"Miyazaki","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0014-2999(92)90045-6","article-title":"Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats","volume":"215","author":"Mizuno","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3175","doi-asserted-by":"crossref","first-page":"PL183","DOI":"10.1016\/0024-3205(92)90627-2","article-title":"Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats","volume":"51","author":"Mizuno","year":"1992","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3180","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/0024-3205(94)90133-3","article-title":"TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin\u2013angiotensin system in spontaneously hypertensive rats","volume":"54","author":"Mizuno","year":"1994","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(95)00401-6","article-title":"Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist","volume":"285","author":"Mizuno","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0024-3205(92)90589-H","article-title":"Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats","volume":"51","author":"Mizuno","year":"1992","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00210-013-0842-7","article-title":"Effects of telmisartan or amlodipine monotherapy versus telmisartan\/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats","volume":"386","author":"Mollnau","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/ndt\/gfr449","article-title":"Protective actions of nebibolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: A comparison with angiotensin II receptor blockade","volume":"27","author":"Moningka","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3205","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.112.201889","article-title":"Hemodynamic and hormonal changes to dual renin\u2013angiotensin system inhibition in experimental hypertension","volume":"61","author":"Moniwa","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1753944711434039","article-title":"Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats","volume":"6","author":"Moniwa","year":"2012","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3215","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/00005344-200006000-00012","article-title":"Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation","volume":"35","author":"Monton","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005344-199307000-00020","article-title":"Sympathoinhibitory effects of losartan in spontaneously hypertensive rats","volume":"22","author":"Moreau","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-9236(97)90180-6","article-title":"The effect of valsartan on the angiotensin II pressure response in healthy normotensive male subjects","volume":"61","author":"Morgan","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjhyper.2006.09.016","article-title":"Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity","volume":"20","author":"Mori","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3235","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1253\/jcj.59.624","article-title":"Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats","volume":"59","author":"Mori","year":"1995","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2009.03.024","article-title":"Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes","volume":"609","author":"Morishima","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3245","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bbrc.2007.03.084","article-title":"Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-\u03b3 activation","volume":"356","author":"Moriuchi","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3250","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1681\/ASN.V6195","article-title":"Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells","volume":"6","author":"Moriyama","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3255","first-page":"S232","article-title":"TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy","volume":"63","author":"Moriyama","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0306-3623(96)02048-4","article-title":"Stimulation of angiotensin subtype 2 receptor reduces basal cGMP levels in the neointima of rat aorta after balloon injury","volume":"28","author":"Moroi","year":"1997","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3265","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.HYP.33.6.1406","article-title":"Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin","volume":"33","author":"Morsing","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000158941","article-title":"Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: Lack of relation to vascular structure","volume":"29","author":"Morton","year":"1992","journal-title":"J Vasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3275","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0002-8703(05)80284-4","article-title":"On the physiologic role of beta-2 adrenoceptors in the human heart: In vitro and in vivo studies","volume":"119","author":"Motomura","year":"1990","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3280","first-page":"322","article-title":"Renoprotective effects of combining ACE inhibitors and statis in experimental diabetic rats","volume":"19","author":"Mudagal","year":"2011","journal-title":"DARU"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/phrs.2000.0767","article-title":"Central inhibition of AT1 receptors by eprosartan - in vitro autoradiography in the brain","volume":"43","author":"Muders","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3290","first-page":"365","article-title":"Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery","volume":"37","author":"Mueck","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3295","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/HYPERTENSIONAHA.108.126524","article-title":"Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats","volume":"53","author":"Mukaddam-Daher","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3300","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00004872-199715090-00014","article-title":"Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy","volume":"15","author":"Mukawa","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cbi.2010.03.008","article-title":"Combination of aspirin with telmisartan suppresses the augmented TGF\u03b2\/smad signaling during the development of streptozotocin-induced type 1 diabetic nephropathy","volume":"185","author":"Mulay","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3310","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/01.ATV.0000237569.95046.b9","article-title":"Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II","volume":"26","author":"Mulders","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02570503","article-title":"Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects","volume":"47","author":"M\u00fcller","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3320","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1074248411434773","article-title":"Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs","volume":"18","author":"M\u00fcller","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3325","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bph.12510","article-title":"Chronic blockade of angiotensin AT1 receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats","volume":"171","author":"M\u00fcller-Fielitz","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3330","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1210\/en.2011-0183","article-title":"Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPAR\u03b3 target gene regulation","volume":"153","author":"M\u00fcller-Fielitz","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3335","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bph.12949","article-title":"Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats","volume":"172","author":"M\u00fcller-Fielitz","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3340","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00210-011-0602-5","article-title":"Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure","volume":"383","author":"M\u00fcller-Fielitz","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3345","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/344541a0","article-title":"Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene","volume":"344","author":"Mullins","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3350","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1992.56","article-title":"Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist","volume":"51","author":"Munafo","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb3355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/16.suppl_1.14","article-title":"Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth","volume":"16","author":"Muniz","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3360","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/HJH.0b013e3283310e1b","article-title":"Long-treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats","volume":"27","author":"Munoz","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3365","doi-asserted-by":"crossref","first-page":"e96948","DOI":"10.1371\/journal.pone.0096948","article-title":"Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylaton in vascular endothelial cells","volume":"9","author":"Myojo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3370","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.HYP.18.1.12","article-title":"Genetic heterogeneity of the spontaneously hypertensive rat","volume":"18","author":"Nabika","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3375","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10557-005-5059-7","article-title":"Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats","volume":"18","author":"Nagai","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/hr.2014.136","article-title":"Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastrolic dysfunction in Dahl salt-sensitive rats","volume":"38","author":"Nagasawa","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3385","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/FJC.0b013e3182592d7b","article-title":"Different roles of PPAR-\u03b3 activity on physiological and pathological alteration after myocardial ischemia","volume":"60","author":"Nagashima","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3390","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bph.12269","article-title":"Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db\/db mice","volume":"170","author":"Nagata","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00395-009-0051-1","article-title":"Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis","volume":"105","author":"Nagy","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3400","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000203619","article-title":"High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: Effects of valsartan and simvastatin","volume":"30","author":"Naito","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3405","first-page":"477","article-title":"Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan","volume":"26","author":"Nakagami","year":"2010","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3410","first-page":"657","article-title":"Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice","volume":"1","author":"Nakagami","year":"2008","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3415","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0014-2999(99)00586-5","article-title":"Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium","volume":"382","author":"Nakai","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3420","first-page":"61","article-title":"Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp)","volume":"5","author":"Nakamura","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3425","first-page":"H2297","article-title":"Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters","volume":"267","author":"Nakamura","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3430","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1254\/jphs.10064SC","article-title":"Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters","volume":"114","author":"Nakamura","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3435","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1046\/j.1523-1755.1999.055003877.x","article-title":"Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis","volume":"55","author":"Nakamura","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3440","first-page":"S226","article-title":"Candesartan prevents the progression of mesangioproliferative nephritis in rats","volume":"63","author":"Nakamura","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3445","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1248\/bpb.b13-00194","article-title":"New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodelling after myocardial infarction","volume":"36","author":"Nakamura","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3450","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mvr.2005.10.002","article-title":"Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patient with essential hypertension","volume":"70","author":"Nakamura","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3455","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/hr.2009.95","article-title":"Telmisartan inhibits cytokine-induced nuclear factor-\u03baB activation independently of the peroxisome proliferator-activated receptor-\u03b3","volume":"32","author":"Nakano","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3460","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00019501-199706000-00003","article-title":"Role of the angiotensin II type 1 receptor in preconditioning against infarction","volume":"8","author":"Nakano","year":"1997","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3465","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00266358","article-title":"Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects","volume":"42","author":"Nakashima","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3470","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5551\/jat.14.133","article-title":"Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPAR\u03b3","volume":"14","author":"Nakaya","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3475","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1016\/S0021-9258(19)78171-X","article-title":"Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells","volume":"269","author":"Nakayama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3480","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1474-8673.2004.00301.x","article-title":"AT1-receptor blockade and sympathetic neurotransmission in cardiovascular disease","volume":"23","author":"Nap","year":"2003","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3485","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/00004872-200209000-00028","article-title":"Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta","volume":"20","author":"Nap","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3490","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.HYP.22.5.780","article-title":"Antihypertensive therapy and adaptive mechanisms in peripheral ischemia","volume":"22","author":"Nelissen-Vrancken","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3495","first-page":"R392","article-title":"Role of intrarenal ANG II in reflex neural stimulation of plasma renin activity and renal sodium reabsorption","volume":"265","author":"Nelson","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3500","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/humrep\/deu035","article-title":"Combined blockade of angiotensin II type I receptor and activation of peroxisome proliferator-activated receptor-\u03b3 by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions","volume":"29","author":"Nenicu","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3505","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.CIR.102.12.1447","article-title":"Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: Effects on left ventricular performance","volume":"102","author":"New","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3510","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI117675","article-title":"Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction","volume":"95","author":"Nio","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3515","first-page":"143","article-title":"Therapeutic interventions using a combination of telmisartan and omega 3-fatty acids in sodium arsenite-induced vascular endothelial dysfunction in rats: Modulation through ATP-sensitive K+ channels and eNOS","volume":"12","author":"Nirwane","year":"2015","journal-title":"J Compl Integr Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3520","first-page":"7","article-title":"Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116","volume":"5","author":"Nishikawa","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3525","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1253\/jcj.59.754","article-title":"Angiotensin II type-1 receptor antagonist as well as angiotensin converying enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats","volume":"59","author":"Nishikimi","year":"1995","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3530","first-page":"856","article-title":"An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarctionin the hypertensive rat","volume":"29","author":"Nishikimi","year":"1995","journal-title":"CVR"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3535","first-page":"1175","article-title":"Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats","volume":"16","author":"Nishimura","year":"1998","journal-title":"J Hypertens"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2016.03.019_bb3540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s003950050221","article-title":"The angiotensin AT1 receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression","volume":"93","author":"Nishimura","year":"1998","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3545","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/jpet.109.158113","article-title":"Mineralocorticoid receptor blockade enhances the antiproteinuric effect of angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats","volume":"332","author":"Nishiyama","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3550","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-2999(92)90184-6","article-title":"Effects of semotidail fumarate (SD-3211) on renal hemodynamics and function in dogs","volume":"218","author":"Nishiyama","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3555","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/01.HYP.29.1.458","article-title":"Improvement of baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction","volume":"29","author":"Nishizawa","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3560","first-page":"F998","article-title":"Effects of angiotensin on renal cortical and papillary blood flows measured by laser-Doppler flowmetry","volume":"261","author":"Nobes","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3565","doi-asserted-by":"crossref","first-page":"16435","DOI":"10.1021\/bi961593m","article-title":"The active state of the AT1 angiotensin receptor is generated by angiotensin II induction","volume":"35","author":"Noda","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3570","first-page":"S136","article-title":"Effects of candesartan cilexetil (TCV-116) and enalapril in 5\/6 nephrectomized rats","volume":"63","author":"Noda","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3575","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.nucmedbio.2012.06.012","article-title":"Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques","volume":"39","author":"Noda","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3580","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1523-1755.1999.00614.x","article-title":"Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure","volume":"56","author":"Noda","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3585","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-2952(93)90420-2","article-title":"Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist","volume":"46","author":"Noda","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3590","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.orcp.2010.11.003","article-title":"Telmisartan suppresses food itnake in mice via the melanocortin pathway","volume":"5","author":"Noma","year":"2011","journal-title":"Obes Res Clin Pract"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2016.03.019_bb3595","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/S0149-2918(04)90141-5","article-title":"Antagonizing the angiotensin II subtype I receptor: A focus on olmesartan medoxomil","volume":"26","author":"Nussberger","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/bbrc.1997.6706","article-title":"Stretch-induced MAP kinase activation in cardiomyocytes of angiotensin-deficient mice","volume":"235","author":"Nyui","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3605","first-page":"S229","article-title":"Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats","volume":"63","author":"Obata","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3610","first-page":"H1824","article-title":"Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy","volume":"273","author":"Obayashi","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3615","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0895-7061(98)00266-0","article-title":"Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded rat","volume":"12","author":"Obayashi","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3620","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2014.02.023","article-title":"Pioglitazone, a PPAR\u03b3 agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat","volume":"730","author":"Ochodnicky","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3625","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1440-1681.1992.tb00480.x","article-title":"Long-term angiotensin II antagonism in spontaneously hypertensive rats: Effects on blood pressure and cardiovascular amplifiers","volume":"19","author":"Oddie","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3630","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00004872-199307000-00006","article-title":"Chronic angiotensin II type 1 antagonism in genetic hypertension: Effects on vascular structure and reactivity","volume":"11","author":"Oddie","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3635","first-page":"S218","article-title":"Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus","volume":"63","author":"O'Donnell","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3640","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.RES.87.11.999","article-title":"Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide\/cGMP signaling and endothelial dysfunction","volume":"87","author":"Oelze","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3645","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00005344-199509000-00021","article-title":"Persistent inhibition of the pressure and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects","volume":"26","author":"Ogihara","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3650","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000139534","article-title":"Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade","volume":"55","author":"Ohlstein","year":"1997","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3655","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-3565(25)10800-8","article-title":"The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism","volume":"262","author":"Ohlstein","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb3660","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00592-007-0016-5","article-title":"Renoprotective effect of telmisartan on renal injury in obese Zucker rats","volume":"49","author":"Ohmura","year":"2012","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3665","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/HYPERTENSIONAHA.111.183178","article-title":"Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance","volume":"59","author":"Ohshima","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3670","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYPERTENSIONAHA.113.02426","article-title":"Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1\u20137) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade","volume":"63","author":"Ohshima","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3675","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3680","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(96)00837-0","article-title":"Candesartan(CV-11794) dissociates slowly from the angiotensin AT1 receptor","volume":"319","author":"Ojima","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3685","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1254\/jphs.09112FP","article-title":"Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats","volume":"111","author":"Okada","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3690","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1248\/bpb.33.1517","article-title":"Effects of captopril and telmisartan on matrix metalloproteinase-2 and -9 expressions and development of left ventricular fibrosis induced by isoprenaline in rats","volume":"33","author":"Okada","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3695","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00005344-199510000-00009","article-title":"Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats","volume":"26","author":"Okada","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3700","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1292\/jvms.09-0582","article-title":"Angiotensin II enhances interleukin-1\u03b2-induced MMP-9 secretion in adult rat cardiac fibroblasts","volume":"72","author":"Okada","year":"2010","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3705","first-page":"75","article-title":"Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist","volume":"5","author":"Okamura","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3710","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-5793(95)00693-4","article-title":"Angiotensin II transduces its signal to focal adhesions via angiotensin II type 1 receptors in vascular smooth muscle cells","volume":"368","author":"Okuda","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3715","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s11064-013-1058-4","article-title":"Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats","volume":"38","author":"Ola","year":"2013","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3720","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1567202612666150104150310","article-title":"Telmisartan promotes potential glucose homeostasis in stroke-resistant spontaneously hypertensive rats via peroxisome proliferator-activated receptor \u03b3 activation","volume":"12","author":"Omote","year":"2015","journal-title":"Curr Neurovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3725","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/cvr\/28.12.1835","article-title":"Transforming growth factor \u03b21 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: Effects of inhibition of the renin\u2013angiotensin system","volume":"28","author":"Omura","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3730","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.bjp.0701458","article-title":"Enhancement by exogenous and locally generated angiotensin II or purinergic neurotransmission via angiotensin type 1 receptor in the guinea-pig isolated mesenteric artery","volume":"122","author":"Onaka","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3735","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db06-1772","article-title":"Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney. Effects of angiotensin II receptor blockers","volume":"57","author":"Onozato","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3740","first-page":"3","article-title":"Na+\/H+ exchange in erythrocytes of spontaneously hypertensive rats: A study in F2 SHRxWKY hybrids","volume":"40","author":"Orlow","year":"1991","journal-title":"Physiol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3745","first-page":"23","article-title":"AngiotensinII induces hypertrophy and hyperplasia in adult human mesangial cells","volume":"3","author":"Orth","year":"1995","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3750","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(93)90703-K","article-title":"Differential responses to angiotensin-(1\u20137) in the fline mesenteric and hindquarters vascular beds","volume":"234","author":"Osei","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3755","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-3565(25)10120-1","article-title":"Analysis of the inhibitory effects of DuP 753 and EXP 3174 on response to angiotensin II in the feline hindquarters vascular bed","volume":"264","author":"Osei","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3760","doi-asserted-by":"crossref","first-page":"II60","DOI":"10.1161\/01.HYP.18.4_Suppl.II60","article-title":"Role of angiotensin II in injury-induced neointima formation in rats","volume":"18","author":"Osterrieder","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3765","first-page":"R1797","article-title":"Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats","volume":"274","author":"Otsuka","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3770","doi-asserted-by":"crossref","first-page":"e42623","DOI":"10.1371\/journal.pone.0042623","article-title":"Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade","volume":"7","author":"Ott","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3775","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/HJH.0b013e32834dde5f","article-title":"Telmisartan ameliorates lipopolysaccharaide-induced innate immune response through peroxisome proliferator-activated receptor-\u03b3 activation in human monocytes","volume":"30","author":"Pang","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3780","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00004872-200108000-00007","article-title":"Persistent cardiovascular effects of chronic renin\u2013angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats","volume":"19","author":"Paull","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3785","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/01.HYP.37.1.91","article-title":"Pharmacodynamic contribution to the vasodilator effect of chronic AT1 receptor blockade in SHR","volume":"37","author":"Paull","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3790","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1440-1681.2001.03443.x","article-title":"The peripheral renin\u2013angiotensin system is not involved in the hypertension of sheep exposed to prenatal dexamethasone","volume":"28","author":"Peers","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3795","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/ajh.2010.241","article-title":"Blockade of AT1 receptors protects the blood\u2013brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats","volume":"24","author":"Pelisch","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3800","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1113\/expphysiol.2014.081596","article-title":"Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan","volume":"99","author":"Penna-de-Carvalho","year":"2014","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3805","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0008-6363(99)00194-7","article-title":"Pressor and mesenteric arterial hyporesponsiveness to angiotensin II is an early event in haemorrhagic hypotension in anaesthetised rats","volume":"44","author":"Pieber","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3810","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ki.1993.257","article-title":"Regulation of renin\u2013angiotensin system in unilateral ureteral obstruction","volume":"44","author":"Pimentel","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3815","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/ndt\/gfm129","article-title":"Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5\/6 nephrectomy","volume":"22","author":"Podjarny","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3820","doi-asserted-by":"crossref","first-page":"C750","DOI":"10.1152\/ajpcell.1992.263.4.C750","article-title":"Effects of angiotensin I and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule","volume":"263","author":"Poggioli","year":"1992","journal-title":"Am J Physiol"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb3825","first-page":"S116","article-title":"Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats","volume":"10","author":"Pollock","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3830","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0022-3565(25)39440-1","article-title":"Angiotensin II receptor blockade improves renal function in rats with reduced renal mass","volume":"267","author":"Pollock","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3835","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.HYP.21.5.660","article-title":"Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition","volume":"21","author":"Pollock","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3840","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.bjp.0701084","article-title":"Trophic effect of angiotensin II in neonatal rat cardiomyocytes: Role of endothelin-1 and non-myocyte cells","volume":"121","author":"P\u00f6nicke","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3845","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1172\/JCI118244","article-title":"Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains","volume":"96","author":"Pravenec","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3850","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00004872-199210120-00003","article-title":"Platelet aggregation in spontaneous hypertension: Genetic determination and correlation analysis","volume":"10","author":"Pravenec","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3855","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s003950070040","article-title":"Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia\/reperfusion injury in the dog heart","volume":"95","author":"Preckel","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3860","article-title":"Immunohistochemical localization of the AT1a, AT1b, and AT2 angiotensin II receptor subtypes in the rat adrenal, pituitary, and brain with a perspective commentary","volume":"213","author":"Premer","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3865","first-page":"1291","article-title":"Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury","volume":"139","author":"Prescott","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3870","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/HJH.0b013e3282f16aaf","article-title":"Effects of combined AT1 receptor antagonist\/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP","volume":"26","author":"Pu","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3875","first-page":"35","article-title":"The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes","volume":"48","author":"Pugsley","year":"2005","journal-title":"Proc West Pharmacol Soc"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3880","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1210\/en.2012-1352","article-title":"Deficiency of angiotensin type 1a receptors in adipocytes reduces differentiation and promotes hypertrophy of adipocytes in lean mice","volume":"153","author":"Putnam","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3885","first-page":"H833","article-title":"Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure","volume":"263","author":"Qing","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3890","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/FJC.0b013e318288a6d7","article-title":"The efficacy and tolerability of azilsartan in mice with left ventricular pressure overload or acute myocardial infarction","volume":"61","author":"Quinn Baumann","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3895","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2015.04.019","article-title":"Comparative effects of aliskiren and telmisartan in high fructose diet-induced metabolic syndrome in rats","volume":"760","author":"Rabie","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3900","first-page":"25","article-title":"Effects of curcumin and telmisartan on olanzapine and high fructose diet induced metabolic syndrome in Sprague Dawley rats","volume":"4","author":"Ramesh Petchi","year":"2012","journal-title":"Pharm J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3905","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0008-6363(96)00210-6","article-title":"Enhanced cardiac preconditionng in the isolated heart of the transgenic ((mREN-2)27) hypertensive rat","volume":"33","author":"Randall","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3910","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1470320310392097","article-title":"Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats","volume":"12","author":"Rao","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3915","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.HYP.4.6.753","article-title":"Dahl salt-susceptible and salt-resistant rats","volume":"4","author":"Rapp","year":"1982","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3920","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/fcp.12054","article-title":"Protective effect of a direct renin inhibitor in acute murine model of cadiotoxicity and nephrotoxicity","volume":"28","author":"Rashikh","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3925","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1476-5381.1993.tb13807.x","article-title":"A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pirthed rat and guinea-pig","volume":"110","author":"Rechtman","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3930","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000020502","article-title":"Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism","volume":"6","author":"Remuzzi","year":"1998","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3935","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2011.09.022","article-title":"Angiotensin II induces nephrin dephosphorylation and podocyte injury: Role of caveolin-1","volume":"24","author":"Ren","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3940","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.HYP.20.3.298","article-title":"Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension","volume":"20","author":"Ribeiro","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3945","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00005344-199307000-00009","article-title":"Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs","volume":"22","author":"Richard","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3950","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0008-6363(98)00227-2","article-title":"Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats","volume":"41","author":"Richer","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3955","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0041-1345(98)01461-4","article-title":"TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model","volume":"31","author":"Richter","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3960","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1021\/jm00077a007","article-title":"6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure\u2013activity relationships","volume":"36","author":"Ries","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3965","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1463-1326.2011.01527.x","article-title":"Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in zucker diabetic fatty rats with metabolic syndrome","volume":"14","author":"Rinaldi","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3970","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.25011\/cim.v35i2.16289","article-title":"Telmisartan-induced eNOS gene expression is partially independent of its PPAR-gamma agonist property","volume":"35","author":"Rios","year":"2012","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3975","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/00005344-199811000-00017","article-title":"Effects of candesartan cilextil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats","volume":"32","author":"Rizzoni","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3980","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0167-0115(94)90029-9","article-title":"Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan","volume":"50","author":"Robertson","year":"1994","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3985","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1476-5381.1994.tb14036.x","article-title":"A pharmacodynamic study of SR 47346, a slective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys","volume":"111","author":"Roccon","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3990","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1523-1755.2004.00789.x","article-title":"AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat","volume":"66","author":"Rodriguez-Iturbe","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb3995","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.11.6.724","article-title":"Mechanisms underlying pressure-related natriuresis: The role of the renin\u2013angiotensin and prostaglandin systems. State of the art lecture","volume":"11","author":"Romero","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4000","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/jpet.109.157099","article-title":"An adipose tissue-independent insulin-sensitizing action of telmisartan: A study in lipodystrophic mice","volume":"331","author":"Rong","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4005","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00125-010-1744-6","article-title":"Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice","volume":"53","author":"Rong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4010","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/HJH.0000000000000506","article-title":"Blockade of the renin\u2013angiotensin system in small arteries and anticontractile function of perivascular adipose tissue","volume":"33","author":"Rosei","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis - an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2009.01.026","article-title":"Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model","volume":"206","author":"Rosseli","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/01.ATV.20.4.949","article-title":"Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN)27 rats via adrenocortical steroid-independent mechanisms","volume":"20","author":"Rossi","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4030","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/698730","article-title":"PPARs in the renal regulation of systemic blood pressure","volume":"2010","author":"R\u00f6szer","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4035","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200108000-00015","article-title":"Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasma reticulum Ca2+ handling in hypertensive transgenic rats overexpressing the Ren2 gene","volume":"19","author":"Rothermund","year":"2001","journal-title":"J Hypertens"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb4040","first-page":"S202","article-title":"Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice","volume":"10","author":"Ruan","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4045","first-page":"H1551","article-title":"Renin\u2013angiotensin system and minoxidil-induced cardiac hypertrophy in rats","volume":"265","author":"Ruzicka","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4050","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.87.3.921","article-title":"The renin\u2013angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker","volume":"87","author":"Ruzicka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(93)90150-G","article-title":"Localization of angiotensin AT1 receptors in the rat heart conduction system","volume":"235","author":"Saavedra","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0006-2952(96)00171-2","article-title":"CV-11974, the active metabolit of TCV-116 (candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells","volume":"52","author":"Sachinidis","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(96)00282-8","article-title":"Carbocyclic thromboxane A2 enhances the angiotensin II-induced DNA synthesis in smooth muscle cells","volume":"307","author":"Sachinidis","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4070","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/00004872-199210000-00008","article-title":"The effect of angiotensin II on DNA synthesis varies considerably in vascular smooth muscle cells from different Wistar-Kyoto rats","volume":"10","author":"Sachinidis","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004872-199302000-00007","article-title":"EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells","volume":"11","author":"Sachinidis","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.metabol.2008.03.014","article-title":"Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin\u2013angiotensin system","volume":"57","author":"Saiki","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4085","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diabet.2009.04.005","article-title":"Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic \u03b2-cells","volume":"35","author":"Saitoh","year":"2009","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4090","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/HJH.0b013e3282f3e9e6","article-title":"The renin\u2013angiotensin system contributes to renal fibrosis through regulation of fibrocytes","volume":"26","author":"Sakai","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4095","first-page":"1245","article-title":"Blockade of angiotensin II type 1 receptor by telmisartan suppressed activation of human hepatic stellate cells","volume":"30","author":"Sakamoto","year":"2009","journal-title":"Ther Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000187524","article-title":"Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats","volume":"65","author":"SAkemi","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00210-012-0810-7","article-title":"Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects","volume":"386","author":"Sakurada","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00210-013-0843-6","article-title":"Cardiac fibroblasts inhibit \u03b2-adrenoceptor dependent connexin43 expression in neonatal rat cardiomyocytes","volume":"386","author":"Salameh","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/HJH.0b013e3282f09f79","article-title":"Renovascular hypertension by two-kidney one-clip enhances endothelial progenitor cell mobilization in a p47phox-dependent manner","volume":"26","author":"Salguero","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1874467211205020282","article-title":"Effects of PPAR\u03b3 ligands on vascular tone","volume":"5","author":"Salomone","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1758-5996-6-57","article-title":"Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats","volume":"6","author":"Salum","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4130","first-page":"440","article-title":"Effect of valsartan and carnitine on cardiomyocyte calpain-1 and Bcl-xl expressions of dogs with chronic alcohol intake-induced cardiomyopathy","volume":"39","author":"Sang","year":"2011","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/hy0202.103002","article-title":"Prorenin-induced myocyte proliferation: No role for intracellular angiotensin II","volume":"39","author":"Saris","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lfs.2012.06.005","article-title":"Nebivolol does not protect against 5\/6 ablation\/infarction induced chronic kidney disease in rats \u2014 Comparison with angiotensin II receptor blockade","volume":"91","author":"Sasser","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4145","first-page":"226","article-title":"Effect of angiotensin II on matrix metalloproteinase-2 secretion from human umbilical vein endothelial cells","volume":"43","author":"Sato","year":"2014","journal-title":"Jpn J Clin Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4150","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.02.019","article-title":"Telmisartan ameliorates inflammatory responses in SHR-SR after tMCAO","volume":"23","author":"Sato","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4155","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.051","article-title":"Telmisartan reduces progressive oxidative stress and phosphorylated \u03b1-synuclein accumulation in stroke-resistant spontaneously hpertensive rats after transient middle cerebral artery occlusion","volume":"23","author":"Sato","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/faat.1996.2248","article-title":"Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist","volume":"35","author":"Sato","year":"1997","journal-title":"Fundam Appl Toxicol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/10641969609081770","article-title":"Role of angiotensin II in reflex tachycardia during hypotension caused by a calcium channel blocker","volume":"18","author":"Sato","year":"1996","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4170","doi-asserted-by":"crossref","first-page":"III346","DOI":"10.1161\/01.CIR.102.suppl_3.III-346","article-title":"Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: Implication of bradykinin-dependent and bradykinin-independent mechanisms","volume":"102","author":"Sato","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4175","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-007-9401-6","article-title":"Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers","volume":"25","author":"Sato","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/hr.2009.190","article-title":"Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats","volume":"33","author":"Satoh","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1549-8719.2009.00010.x","article-title":"In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats","volume":"17","author":"Satoh","year":"2010","journal-title":"Microcirculation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4190","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/HYPERTENSIONAHA.107.104570","article-title":"Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system. Role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor \u03b3 signaling during endothelial aging","volume":"51","author":"Scalera","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.phrs.2007.05.009","article-title":"Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus","volume":"56","author":"Sch\u00e4fer","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1476-5381.1994.tb16899.x","article-title":"Mutations in transmembrane segment VII of the AT1 receptor differentite between closely related insurmountable and competitive angiotensin antagonists","volume":"113","author":"Schambye","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1159\/000159254","article-title":"Local application of angiotensin II to the rat carotid artery induces adventitial thickening","volume":"34","author":"Scheidegger","year":"1997","journal-title":"J Vasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/00004872-199715120-00013","article-title":"Structural adaptation to ischemia in skeletal muscle: Effects of blockers of the renin\u2013angiotensin system","volume":"15","author":"Scheidegger","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4215","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0022-3565(25)20779-0","article-title":"Effects of prolonged blockade of the renin angiotensin system on strited muscle microcirculation of spontaneously hypertensive rats","volume":"278","author":"Scheidegger","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4220","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI116139","article-title":"Cytoskeleton-dependent endocytosis is required for apical type 1 angiotensin II receptor-mediated phospholipase C activation in cultured rat proximal tubule cells","volume":"90","author":"Schelling","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4225","first-page":"R917","article-title":"Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin","volume":"364","author":"Scheuer","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/147323000102900210","article-title":"Effects of telmisartan on renal excretory function in conscious dogs","volume":"29","author":"Schierok","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4235","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/HJH.0b013e328349ae0d","article-title":"Coexistence of functional angiotensin II type 2 receptor mediating both vasoconstriction and vasodilation in humans","volume":"29","author":"Schinzari","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4240","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1476-5381.2011.01267.x","article-title":"Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis","volume":"163","author":"Schlimmer","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4245","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0895-7061(00)00266-1","article-title":"Effects of acute and chronic angiotensin receptor blockade on myocardial vascular blood volume and perfusion in a pig model of coronary microembolization","volume":"13","author":"Schmermund","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4250","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.RES.72.6.1245","article-title":"Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts","volume":"72","author":"Schorb","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4255","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0022-2828(95)90051-9","article-title":"Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts","volume":"27","author":"Schorb","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4260","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1111\/bph.13172","article-title":"Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1\u20137)\/mas-dependent pathway","volume":"172","author":"Schuchard","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4265","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-199917121-00016","article-title":"No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats","volume":"17","author":"Schuijt","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4270","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1038\/508S50a","article-title":"Public health: Society at large","volume":"508","author":"Scully","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4275","first-page":"F236","article-title":"Distribution of angiotensin II receptor subtypes in rat and human kidney","volume":"262","author":"Sechi","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4280","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/01.RES.71.6.1482","article-title":"Characterization of angiotensin II receptor subtypes in rat heart","volume":"71","author":"Sechi","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4285","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2362.2009.02183.x","article-title":"Effect of AT1- and \u03b2-adrenergic receptor antagonists on TGF-\u03b21-induced fibrosis in transgenic mice","volume":"39","author":"Seeland","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4290","first-page":"266","article-title":"Coparative effect of angiotensin II type I receptor blockers on blood glucose concentration and oxidative stress in streptozotocin-induced diabetic rats","volume":"6","author":"Senapathy","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","article-title":"Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomised controlled trials","volume":"216","author":"Shahin","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4300","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/aps.2011.88","article-title":"Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats","volume":"32","author":"Shang","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1081\/CEH-100102662","article-title":"Obese female SHHF\/Mcc-facp rats resist antibhypertensive effects of renin\u2013angiotensin system inhibition","volume":"23","author":"Sharkey","year":"2001","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4310","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00005344-199905000-00014","article-title":"Role of angiotensin in cardioprotective effect of ischemic preconditioning","volume":"33","author":"Sharma","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pbb.2012.03.029","article-title":"Experimental hypertension induced vascular dementia: Pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor","volume":"102","author":"Sharma","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4320","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1470320313475908","article-title":"Dual therapy of vildagliptin and telmisartan on diabeic nephropathy in experimentally induced type 2 diabetes mellitus rats","volume":"15","author":"Sharma","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4325","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3565(24)39054-8","article-title":"Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan","volume":"294","author":"Shetty","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2016.03.019_bb4330","first-page":"S115","article-title":"TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats","volume":"55","author":"Shibouta","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4335","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(25)38306-0","volume":"266","author":"Shibouta","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s13340-013-0135-x","article-title":"Olmesartan and telmisartan comparably preserve pancreatic beta-cell mass with reduction of oxidative stress in db\/db mice","volume":"5","author":"Shigahara","year":"2014","journal-title":"Diabetol Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4345","first-page":"113","article-title":"Effects of angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats","volume":"5","author":"Shimamoto","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4350","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.nucmedbio.2012.01.008","article-title":"Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3","volume":"39","author":"Shimizu","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00005344-199907000-00013","article-title":"The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts","volume":"34","author":"Shimizu","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4360","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2012.07.026","article-title":"Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects","volume":"692","author":"Shiota","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4365","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1475-2840-11-139","article-title":"Telmisartan ameliorates insulin sensitivity by activating the AMPK\/SIRT1 pathway in skeletal muscle of obese db\/db mice","volume":"11","author":"Shiota","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4370","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.phrs.2010.10.010","article-title":"Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries","volume":"63","author":"Siarkos","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4375","first-page":"R1276","article-title":"Angiotensin II: Nitric oxide interaction and the distribution of blood flow","volume":"265","author":"Sigmon","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.HYP.22.2.237","article-title":"Renal nitric oxide and angiotensin II interaction in renovascular hypertension","volume":"22","author":"Sigmon","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3810\/pgm.2004.08.1569","article-title":"ARBs and target organ protection","volume":"116","author":"Silverstein","year":"2004","journal-title":"Postgrad Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4390","first-page":"135","article-title":"Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy","volume":"5","author":"Singh","year":"2006","journal-title":"Iran J Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4395","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/ATVBAHA.112.300985","article-title":"Telmisartan exerts pleiotropic effects in endothelial cells and promotes entohelial cell quiescence and survival","volume":"33","author":"Siragusa","year":"2013","journal-title":"Aterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4400","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin\u2013angiotensin-aldosterone system in chronic kidney disaease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4405","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1113\/expphysiol.2007.040550","article-title":"Renal (pro)renin upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity","volume":"93","author":"Siragy","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4410","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.HYP.35.5.1074","article-title":"Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats","volume":"35","author":"Siragy","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4415","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.bjp.0702366","article-title":"Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney","volume":"126","author":"Smart","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4420","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.HYP.22.2.221","article-title":"Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation","volume":"22","author":"Smits","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4425","first-page":"772","article-title":"Angiotensin II receptor blockade after myocardial infarction in rats: Effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content","volume":"20","author":"Smits","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4430","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1124\/jpet.113.212613","article-title":"Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: Role of vascular endothelial growth factors A and B","volume":"349","author":"Soliman","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4435","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0022-3565(25)38388-6","article-title":"Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats","volume":"266","author":"Soltis","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4440","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10641969309041618","article-title":"Acute and chronic effects of losartan (DuP 753) on blood pressure and vascular reactivity in normotensive rats","volume":"15","author":"Soltis","year":"1993","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4445","first-page":"2628","article-title":"Effects of telmisartan on inflammation and fibrosis after acute myocardial infarction in rts","volume":"94","author":"Song","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4450","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/ndt\/gfr621","article-title":"Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment","volume":"27","author":"Song","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4455","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1476-5381.1991.tb12503.x","article-title":"Access of peripherally administered CuP 753 to rat brain angiotensin receptors","volume":"104","author":"Song","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4460","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/FJC.0b013e3182646ccc","article-title":"Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNF\u03b1-stimulated human endothelial cells and reduce associated atherogenicity","volume":"60","author":"Sonoki","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4465","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/CS20100061","article-title":"Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insuline resistance, and liver and pancreas remodelling in C57BL\/g mice fed on a very high-fat diet","volume":"119","author":"Souza-Mello","year":"2010","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4470","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0b013e3182153922","article-title":"Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL\/6 mice","volume":"40","author":"Souza-Mello","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4475","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00210-007-0238-7","article-title":"Brain angiotensin receptors and binding proteins","volume":"377","author":"Speth","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4480","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0022-3565(24)37129-0","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: Differential effects on myocyte contractile processes","volume":"283","author":"Spinale","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4485","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00005344-199711000-00013","article-title":"Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: Effects on ventricle and myocyte function","volume":"30","author":"Spinale","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4490","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1071-9164(98)90238-X","article-title":"Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: Cellular mechanisms of action","volume":"4","author":"Spinale","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4495","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1161\/01.CIR.96.7.2397","article-title":"Modulation of the renin\u2013angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes","volume":"96","author":"Spinale","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4500","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/009127000004001209","article-title":"The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4505","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00005344-200111000-00004","article-title":"Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge","volume":"38","author":"Stangier","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4510","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-9556(25)08584-8","article-title":"The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4515","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1582-4934.2009.00829.x","article-title":"Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells","volume":"14","author":"Steinmetz","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4520","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2362.2008.02025.x","article-title":"Angiotensin inhibition stimulates PPAR\u03b3 and the release of visfatin","volume":"38","author":"Storka","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4525","first-page":"CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","volume":"4","author":"Strippoli","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4530","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0300-9572(97)00023-3","article-title":"Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pgs","volume":"35","author":"Strohmenger","year":"1997","journal-title":"Resuscitation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4535","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0165-6147(90)90251-3","article-title":"Remodeling of the vascular tree in hypertension: Drug effects","volume":"11","author":"Struyker-Boudier","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4540","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cvr\/cvp091","article-title":"Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src\/PI3K\/Akt signalling","volume":"82","author":"Su","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4545","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.CIR.87.3.931","article-title":"Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies","volume":"87","author":"Sudhir","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4550","first-page":"111","article-title":"Binding properties of telmisartan (Micardis) for human angiotensin II receptors","volume":"13","author":"Sudoh","year":"2003","journal-title":"Clin Pharmacol Ther (Tokyo)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4555","doi-asserted-by":"crossref","first-page":"e000035","DOI":"10.1161\/JAHA.113.000035","article-title":"Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome - the critical role of angiotensin II","volume":"2","author":"Sueta","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4560","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ajh\/hpu076","article-title":"Telmisartan exerts sustained blood pressure control and reduces blood pressure vaiability in metabolic syndrome by inhibiting sympathetic activity","volume":"27","author":"Sueta","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4565","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1440-1681.1996.tb02824.x","article-title":"AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats","volume":"23","author":"Sugimoto","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4570","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/HJH.0b013e3282f9b58a","article-title":"Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-\u03b3 dependent pathway","volume":"26","author":"Sugimoto","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4575","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/01.HYP.0000215181.60228.f7","article-title":"Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis","volume":"47","author":"Sugimoto","year":"2006","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb4580","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/sj.jhh.1000743","article-title":"Effects of candesartan cilexitil on oxidative state and renal function in 5\/6 nephrectomized rats","volume":"13","author":"Sugimoto","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4585","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10157-012-0759-3","article-title":"Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP-Z-Leprfa\/IzmDmcr rats","volume":"17","author":"Sugiyama","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4590","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gfi045","article-title":"Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral obstruction in acatalasemic mice","volume":"20","author":"Sugiyama","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4595","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4600","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","article-title":"Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2\/angiotensin 1\u20137\/mas receptor axis","volume":"7","author":"Sukumaran","year":"2011","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejphar.2010.10.081","article-title":"Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress","volume":"652","author":"Sukumaran","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4610","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lfs.2011.11.018","article-title":"Telmisartan acts through the modulation of ACE-2\/ANG 1\u20137\/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis","volume":"90","author":"Sukumaran","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4615","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2010.67","article-title":"Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodelling in rats with dilated cardiomyopathy","volume":"33","author":"Sukumaran","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4620","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-3565(25)22812-9","article-title":"Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle","volume":"271","author":"Sung","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4625","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jash.2014.02.009","article-title":"Telmisartan improves survivial and ventricular function in SHR rats with extensive cardiovascular damage induced by dietary salt excess","volume":"8","author":"Susic","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4630","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1074248412458155","article-title":"Telmisartan prevents excess-salt-induced exacerbated (malignant) hypertension in spontaneously hypertensive rats","volume":"18","author":"Susic","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4635","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1291\/hypres.24.65","article-title":"Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure","volume":"24","author":"Suzuki","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4640","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1291\/hypres.30.521","article-title":"Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension","volume":"30","author":"Syrbe","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4645","first-page":"38","article-title":"Topical application of AT1 receptor antagonists prevents medial and neotintimal proliferation after balloon injury","volume":"5","author":"Taguchi","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4650","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1006\/bbrc.1993.2344","article-title":"Angiotensin converting enzyme inhibitors of DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application","volume":"196","author":"Taguchi","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4655","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/hr.2012.187","article-title":"Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats","volume":"36","author":"Takai","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4660","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/hr.2009.116","article-title":"Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats","volume":"32","author":"Takai","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4665","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1291\/hypres.30.1231","article-title":"Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferated-activated receptor \u03b3 agonistic property in rats","volume":"30","author":"Takai","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4670","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/hr.2010.90","article-title":"Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats","volume":"33","author":"Takai","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4675","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1254\/jphs.13167FP","article-title":"Significance of the vascular concentration of angiotensin II-receptor blockers on the mechanism of lowering blood pressure in spontaneously hypertensive rats","volume":"123","author":"Takai","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4680","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/hr.2010.224","article-title":"Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats","volume":"34","author":"Takai","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4685","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000151294","article-title":"Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells","volume":"29","author":"Takao","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4690","doi-asserted-by":"crossref","first-page":"333","DOI":"10.59566\/IJBS.2006.2333","article-title":"An angiotensin II (Ang II) type 1 receptor blocker, telmisartan, improves insulin resistance in KK-Ay diabetic mice","volume":"2","author":"Takasu","year":"2006","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4695","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.atherosclerosis.2005.08.009","article-title":"Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apoliprotein E-deficient mice","volume":"186","author":"Takaya","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4700","first-page":"94","article-title":"Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats","volume":"5","author":"Takeda","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4705","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1161\/01.HYP.30.6.1621","article-title":"Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitrix oxide synthesis","volume":"30","author":"Takemoto","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4710","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.yjmcc.2006.07.019","article-title":"Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension","volume":"41","author":"Takenaka","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4715","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/hr.2012.199","article-title":"Telmisartan modulates mitochondrial function in vascular smooth muscle cells","volume":"36","author":"Takeuchi","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4720","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/mol.115.099176","article-title":"Structure-function basis of attenuated inverse agonism of angiotensin II type 1 receptor blockers for active-state angiotensin II type 1 receptors","volume":"88","author":"Takezako","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4725","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/01.HYP.24.4.445","article-title":"Short-term effects of angiotensin II blockade on renal blood flow and sympathetic activity in awake rats","volume":"24","author":"Takishita","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4730","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00535-012-0651-7","article-title":"Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis","volume":"48","author":"Tamaki","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4735","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005344-199711000-00011","article-title":"Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist","volume":"30","author":"Tamura","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4740","first-page":"205","article-title":"Regulation of cardiac angiotensinogen mRNA in vivo and in vitro","volume":"12","author":"Tamura","year":"1997","journal-title":"Heart Vessels Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4745","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/01.CIR.90.4.2051","article-title":"An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis","volume":"90","author":"Tanaka","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4750","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2011.06.052","article-title":"Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats","volume":"162","author":"Tang","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4755","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diabres.2012.01.037","article-title":"Valsartan inhibited HIF-1\u03b1 pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats","volume":"97","author":"Tang","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4760","first-page":"H1385","article-title":"Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure","volume":"276","author":"Tanimura","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4765","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.102.2.246","article-title":"Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters","volume":"102","author":"Taniyama","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4770","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FJC.0b013e31829f0c1b","article-title":"The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload","volume":"62","author":"Tarikuz Zaman","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4775","first-page":"600","article-title":"Renoprotective activity of telmisartan versus pioglitazone on ischemia\/reperfusion induced renal danage in diabetic rats","volume":"16","author":"Tawfik","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4780","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3565(24)38035-8","article-title":"Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery","volume":"288","author":"Tazawa","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4785","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/01.HYP.35.5.1069","article-title":"Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo","volume":"35","author":"Tea","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4790","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00004872-199508000-00009","article-title":"Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats","volume":"13","author":"Teruya","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4795","doi-asserted-by":"crossref","first-page":"e23646","DOI":"10.1371\/journal.pone.0023646","article-title":"Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models","volume":"6","author":"Thoene-Reineke","year":"2011","journal-title":"PLoS One"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb4800","first-page":"S220","article-title":"AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries","volume":"10","author":"Thorup","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4805","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/01.CIR.98.19.2037","article-title":"Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension","volume":"98","author":"Th\u00fcrmann","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4810","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/HYPERTENSIONAHA.108.126656","article-title":"Inhibition of tumor necrosis factor-\u03b1-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-\u03b3 with nuclear factor \u03baB and CCAAT\/Enhanced-binding protein-\u03b2","volume":"53","author":"Tian","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4815","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/187153011795564133","article-title":"Functional relevance of biased signaling at the angiotensin II type 1 receptor","volume":"11","author":"Tilley","year":"2011","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4820","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2840-12-30","article-title":"AT1 receptor deficiency induced atheroprotection in diabetic mice is partially mediated by PPAR\u03b3","volume":"12","author":"Tiyerili","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4825","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.yjmcc.2011.12.007","article-title":"Stimulation of the AT2 receptor reduced ahterogenesis in apoE-\/-\/AT1A-\/- double knock out mice","volume":"52","author":"Tiyerili","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4830","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2012.01.026","article-title":"Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-\u03b3 in subtotal nephrectomized rat","volume":"685","author":"Toba","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4835","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000355482","article-title":"Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-\u03b3 activation in hypertensive 5\/6 nephrectomized rats","volume":"92","author":"Toba","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4840","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.HYP.18.6.774","article-title":"Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats","volume":"18","author":"Tofovic","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4845","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/DMSO.S78771","article-title":"Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation","volume":"8","author":"Tojo","year":"2015","journal-title":"Diabetol Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4850","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1440-1797.2009.01143.x","article-title":"Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model","volume":"14","author":"Tominaga","year":"2009","journal-title":"Nephrology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4855","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3892\/mmr_00000164","article-title":"Combination therapy based on the angiotensin receptor blocker olmesartan for vascular protection in spontaneously hypertensive rats","volume":"2","author":"Tomita","year":"2009","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4860","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ajh.2007.50","article-title":"Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models","volume":"21","author":"Tomono","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4865","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/bbrc.1998.9767","article-title":"Angiotensin II interferes with leukemia inhibitory factor-induced STAT3 activation in cardiac myocytes","volume":"253","author":"Tone","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4870","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-8993(93)91299-8","article-title":"Functional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response","volume":"603","author":"Toney","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4875","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00210-015-1112-7","article-title":"Reno-protection of G004, a novel anti-diabetic sulfonylurea in db\/db mice","volume":"388","author":"Tong","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4880","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/01.HYP.37.2.574","article-title":"p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY","volume":"37","author":"Touyz","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4885","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00004872-200103001-00006","article-title":"Differential activation of extracellular signal-regulated protein kinase 1\/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats","volume":"19","author":"Touyz","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4890","doi-asserted-by":"crossref","first-page":"13657","DOI":"10.1074\/jbc.M008101200","article-title":"Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms","volume":"276","author":"Touyz","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4895","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbrc.2011.06.012","article-title":"Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-\u03b3-dependent activity","volume":"410","author":"Toyama","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl. 11","key":"10.1016\/j.pharmthera.2016.03.019_bb4900","first-page":"S184","article-title":"Renin\u2013angiotensin system dependence of renal hemodynamics in mice","volume":"10","author":"Traynor","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4905","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0022-3565(25)24448-2","article-title":"Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure","volume":"272","author":"Trippodo","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4910","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/01.CIR.91.9.2415","article-title":"Age and hypertension differently affect coronary contractions to endothelin-1, serotin, and angiotensins","volume":"91","author":"Tschudi","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4915","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/00004872-199917070-00007","article-title":"Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR","volume":"17","author":"Tsuchihashi","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4920","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1161\/01.HYP.0000157409.88971.fc","article-title":"Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress","volume":"45","author":"Tsuda","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4925","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3317\/jraas.2007.017","article-title":"Renoprotective effects of telmisartan in the 5\/6 nephrectomized rats","volume":"8","author":"Tsunenari","year":"2005","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4930","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1681\/ASN.2007020160","article-title":"Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury","volume":"19","author":"Tu","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4935","doi-asserted-by":"crossref","first-page":"299fs32","DOI":"10.1126\/scitranslmed.aac9412","article-title":"Neuroprotective therapies: Preclinical reproducibility is only part of the problem","volume":"7","author":"Tymiianski","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4940","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejphar.2012.11.022","article-title":"Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice","volume":"698","author":"Ushijima","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4945","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00004872-199506000-00015","article-title":"Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development","volume":"13","author":"Vacher","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4950","first-page":"R676","article-title":"Endogenous angiotensin II modulates the effect of atrial natriuretic peptide on extracellular fluid partition","volume":"264","author":"Valentin","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4955","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1097\/HJH.0b013e32834a7667","article-title":"Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism","volume":"29","author":"van der Zijl","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4960","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.102.13.1556","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling pigs after myocardial infarction: Role of tissue angiotensin II","volume":"102","author":"van Kats","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4965","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4970","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/bjs.1800810609","article-title":"Influence of losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein","volume":"81","author":"Varty","year":"1994","journal-title":"Br J Surg"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4975","doi-asserted-by":"crossref","first-page":"901371","DOI":"10.1155\/2014\/901371","article-title":"Sunitinib cobined with angiotensin-2 type-1 receptor antagonists induces more necrosis: A murine xenograft model of renal cell carcinoma","volume":"2014","author":"Verhoest","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4980","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4985","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1093\/ndt\/gfr096","article-title":"Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis","volume":"26","author":"Villa","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4990","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/path.4151","article-title":"Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: New insights into mechanisms","volume":"229","author":"Villa","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb4995","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1161\/01.CIR.88.6.2849","article-title":"Identification of functional angiotensin II receptors on rat cardiac fibroblasts","volume":"88","author":"Villareal","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5000","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1161\/01.STR.0000190002.79052.bf","article-title":"Constrictor and dilator effects of angiotensin II on cerebral arterioles","volume":"36","author":"Vincent","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5005","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.bjp.0700897","article-title":"In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation","volume":"120","author":"Virone-Oddos","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5010","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1172\/JCI116043","article-title":"Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta","volume":"90","author":"Viswanathan","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00004872-199209000-00006","article-title":"Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats","volume":"10","author":"von Lutterotti","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/CIRCULATIONAHA.106.664854","article-title":"C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice","volume":"115","author":"Vongpatanasin","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00004872-199507000-00007","article-title":"Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation","volume":"13","author":"Vraamark","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1291\/hypres.19.75","article-title":"Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexteil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats","volume":"19","author":"Wada","year":"1996","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(94)90753-6","article-title":"Effect of an angiotensin II recetpro antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone","volume":"253","author":"Wada","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004872-199501000-00017","article-title":"Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats","volume":"13","author":"Wada","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1291\/hypres.19.247","article-title":"Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats","volume":"19","author":"Wada","year":"1996","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/10641969809053215","article-title":"Effects of AT1 receptor blockade on blood pressure and the renin\u2013angiotensin system in spontaneously hypertensive rats of the stroke prone strain","volume":"20","author":"Wagner","year":"1998","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WNR.0b013e328346be84","article-title":"Effects of valsartan on neuroprotection and neurogenesis after ischemia","volume":"22","author":"Wakai","year":"2011","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.107.099028","article-title":"Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-\u03b3","volume":"51","author":"Walcher","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-3565(25)10995-6","article-title":"Renin\u2013angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats","volume":"261","author":"Wang","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5070","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00210-012-0740-4","article-title":"Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway","volume":"385","author":"Wang","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.lfs.2011.11.015","article-title":"Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin actin in rats on high-fat diet","volume":"90","author":"Wang","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7555\/JBR.26.20120013","article-title":"Telmisartan prevents high-fat diet-induced hypertension and decreases perirenal fat in rats","volume":"26","author":"Wang","year":"2012","journal-title":"J Biomed Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5085","first-page":"2200","article-title":"Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.yjmcc.2007.11.019","article-title":"RGS5, RGS4, and RGS2 expression and aortic contractibility are dynamically co-regulated during aortic banding-induced hypertrophy","volume":"44","author":"Wang","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5095","first-page":"660","article-title":"The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy","volume":"48","author":"Wang","year":"2009","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5100","first-page":"267","article-title":"Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats","volume":"119","author":"Wang","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1745-7254.2006.00381.x","article-title":"Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats","volume":"27","author":"Wang","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.CIR.103.3.435","article-title":"Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats","volume":"103","author":"Wassmann","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/01.HYP.0000153321.13792.b9","article-title":"Angiotensin II and the endothelium: Diverse signals and effects","volume":"45","author":"Watanabe","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/10641969809052119","article-title":"Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats","volume":"20","author":"Webb","year":"1998","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0895-7061(97)00309-9","article-title":"Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR)","volume":"11","author":"Webb","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: A statement by the Amcerican Society of Hypertension and the International Society of Hypertension","volume":"16","author":"Weber","year":"2014","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5135","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/01.CIR.95.6.1592","article-title":"Angiotensin AT1 receptor inhibition. Effects on hypertrophy remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis","volume":"95","author":"Weinberg","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.freeradbiomed.2008.05.009","article-title":"AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats","volume":"45","author":"Wenzel","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000329327","article-title":"Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin","volume":"34","author":"Whaley-Connell","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5150","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1476-5381.1993.tb12861.x","article-title":"Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats","volume":"108","author":"Widdop","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199402000-00003","article-title":"Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat","volume":"12","author":"Wienen","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3317\/jraas.2001.013","article-title":"Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats","volume":"2","author":"Wienen","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1527-3466.2000.tb00039.x","article-title":"A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist","volume":"18","author":"Wienen","year":"2000","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5175","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0026-895X(25)09255-7","article-title":"Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies","volume":"41","author":"Wienen","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3317\/jraas.2001.005","article-title":"Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats","volume":"2","author":"Wienen","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5185","first-page":"733","article-title":"Angiotensin inhibition and natriuretic peptide release after acute volume expansion in rats with aortocaval shunt","volume":"42","author":"Willenbrock","year":"1999","journal-title":"CVR"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: From orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5195","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1074\/jbc.M113.472381","article-title":"The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negative regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers","volume":"288","author":"Wilson","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5200","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1210\/endo-124-6-2799","article-title":"Angiotensin II and atrial natriuretic factor-binding sites in various tissues in hypertension: Comparative receptor localization and changes in different hypertension models in the rat","volume":"124","author":"Wilson","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000020513","article-title":"AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis","volume":"6","author":"Wolf","year":"1998","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/01.HYP.15.6.823","article-title":"Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753","volume":"15","author":"Wong","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0022-3565(25)19986-2","article-title":"Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity of DuP 753, an orally active antihypertensive agent","volume":"252","author":"Wong","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5220","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-3565(25)19984-9","article-title":"Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent","volume":"252","author":"Wong","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.15.5.459","article-title":"Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X","volume":"15","author":"Wong","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(25)12755-9","article-title":"Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent","volume":"255","author":"Wong","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5235","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/01.HYP.19.6.663","article-title":"Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function","volume":"19","author":"Wong","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5240","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1172\/JCI116357","article-title":"Role of AT1 receptors in the resetting of the baroreflex control of heart rate by angiotensin II in the rabbit","volume":"91","author":"Wong","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1113\/jphysiol.2007.138578","article-title":"Involvement of an enterocyte renin\u2013angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane","volume":"584","author":"Wong","year":"2007","journal-title":"J Physiol Lond"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1152\/physiolgenomics.2000.4.1.35","article-title":"Gene expression in rts with renal disease treated with the angiotensin II receptor antagonist, erposartan","volume":"4","author":"Wong","year":"2000","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5255","first-page":"F908","article-title":"Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model","volume":"307","author":"Wong","year":"2014","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5260","first-page":"30","article-title":"Effects of telmisartan on the expression of adiponectin receptor 1 in cardiomyocytes and its mechanism","volume":"40","author":"Wu","year":"2015","journal-title":"Med J Chin PLA"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5265","first-page":"F929","article-title":"A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren","volume":"299","author":"Wu","year":"2010","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5270","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/ki.1997.214","article-title":"Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin\u2013angiotensin system","volume":"51","author":"Wu","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5275","first-page":"453","article-title":"The protective effect of telmisartan in type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein","volume":"36","author":"Wu","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5280","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibtrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5285","first-page":"F600","article-title":"Regulation of urinary ACE2 in diabetic mice","volume":"305","author":"Wysocki","year":"2013","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5290","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.ATV.19.1.73","article-title":"Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells","volume":"19","author":"Xi","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/jpet.104.065185","article-title":"Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: Evidence for two distinct mechanisms for endothelin regulation","volume":"310","author":"Xia","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5300","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-002-0990-y","article-title":"The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart","volume":"445","author":"Xiao","year":"2003","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/10641969909068675","article-title":"Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade","volume":"21","author":"Xie","year":"1999","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2006.05.034","article-title":"Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs","volume":"543","author":"Xie","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5315","first-page":"2860","article-title":"Effect of telmisartan on tubulointerstitial injury and expression of PPAR\u03b3 in rat renal tissue of IgA nephropathy model","volume":"90","author":"Xing","year":"2010","journal-title":"Natl Med J China"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.33549\/physiolres.932433","article-title":"Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K\/Akt\/eNOS pathway and NO release in spontaneously hypertensive rats","volume":"62","author":"Xu","year":"2013","journal-title":"Physiol Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5325","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1113\/expphysiol.2008.045583","article-title":"The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice","volume":"94","author":"Xu","year":"2009","journal-title":"Exp Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5330","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2015.06.005","article-title":"Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs","volume":"762","author":"Xu","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5335","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3892\/ijmm.2014.1834","article-title":"Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of the peroxisome proliferator-activated receptor-\u03b4 pathway","volume":"34","author":"Xu","year":"2014","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5340","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11596-011-0374-7","article-title":"Telmisartan protects against insulin resistance by attenuating inflammatory response in rats","volume":"31","author":"Xu","year":"2011","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5345","first-page":"H555","article-title":"Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension","volume":"300","author":"Xue","year":"2011","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5350","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1291\/hypres.31.601","article-title":"Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro","volume":"31","author":"Yamada","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5355","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.07.003","article-title":"Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke","volume":"16","author":"Yamada","year":"2007","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5360","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/00004872-199512010-00021","article-title":"The effect of central amino acid neurotransmitters on the antihypertensive response to angiotensin blockade in spontaneous hypertension","volume":"13","author":"Yamada","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5365","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1006\/jmcc.1993.1149","article-title":"Contribution of cardiac renin\u2013angiotensin system to ventricular remodelling in myocardial-infarcted rats","volume":"25","author":"Yamagishi","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5370","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2174\/092986608785203746","article-title":"Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-\u03b3 activation","volume":"15","author":"Yamagishi","year":"2008","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5375","first-page":"630","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: Hemodynamic effects of valsartan in dog heart failure models","volume":"47","author":"Yamamoto","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5380","first-page":"604","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: Antihypertensive effects of valsartan in hypertensive models","volume":"47","author":"Yamamoto","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5385","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/HYPERTENSIONAHA.109.133884","article-title":"Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice","volume":"54","author":"Yamamoto","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5390","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/HYPERTENSIONAHA.109.138750","article-title":"Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-\u03b3 activation","volume":"54","author":"Yamamoto","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5395","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1211\/jpp.58.11.0011","article-title":"Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4","volume":"58","author":"Yamashita","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5400","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.04.010","article-title":"Strong improvement of apolipoprotein E\/low-density lipoprotein receptor signals by telmisartan in poststroke spontaneuously hypertensive stroke resistant","volume":"23","author":"Yamashita","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb5405","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/sj.jhh.1000747","article-title":"Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress","volume":"13","author":"Yamazaki","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5410","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/01.RES.82.4.430","article-title":"Role of ion channels and exchangers in mechanical stretch-induced cardiomoycyte hypertrophy","volume":"82","author":"Yamazaki","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5415","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1074\/jbc.271.6.3221","article-title":"Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy","volume":"271","author":"Yamazaki","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5420","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.RES.77.2.258","article-title":"Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy","volume":"77","author":"Yamazaki","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5425","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00408658","article-title":"Molecular aspects of mechanical stress-induced cardiac hypertrophy","volume":"163-164","author":"Yamazaki","year":"1996","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5430","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/jm950450f","article-title":"Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure\u2013activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds","volume":"39","author":"Yanagisawa","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5435","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/01.HYP.33.1.335","article-title":"Angiotensin II type 1 receptor-mediated peroxide production in human macrophages","volume":"33","author":"Yanagitani","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5440","first-page":"3640","article-title":"Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus","volume":"123","author":"Yang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5445","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/01.HYP.20.6.755","article-title":"Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats","volume":"20","author":"Yang","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5450","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.HYP.19.5.475","article-title":"Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus","volume":"19","author":"Yang","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-009-0098-1","article-title":"Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4\/NF-\u03baB signaling pathway","volume":"330","author":"Yang","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5460","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1745-7254.2007.00541.x","article-title":"Effect of telmisartan on expression of protein kinase C-\u03b1 in kidneys of diabetic mice","volume":"28","author":"Yao","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5465","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11596-008-0512-z","article-title":"Telmisartan but not valsartan inhibits TGF-\u03b2-mediated accumulation of extracellular matrix via activation of PPAR\u03b3","volume":"28","author":"Yao","year":"2008","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5470","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1248\/bpb.18.687","article-title":"Role of angiotensin II in the transforming growth factor-\u03b21 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritisis","volume":"18","author":"Yayama","year":"1995","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5475","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1248\/bpb.18.411","article-title":"Activation of the renin\u2013angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis","volume":"18","author":"Yayama","year":"1995","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5480","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0014-2999(93)90609-L","article-title":"Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis","volume":"236","author":"Yayama","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5485","first-page":"312","article-title":"Influence of telmisartan on peripheral calcineurin of rat with two kidneys one clip hypertension","volume":"26","author":"Ye","year":"2010","journal-title":"Chin Pharmacol Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5490","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10557-011-6339-z","article-title":"Aliskiren and valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice","volume":"25","author":"Ye","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5495","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5500","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/aps.2012.115","article-title":"Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats","volume":"33","author":"Yi","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5505","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/07435800.2013.828741","article-title":"Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells","volume":"39","author":"Yin","year":"2014","journal-title":"Endocr Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5510","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/cr.2008.69","article-title":"Angiotensin II promotes NO production, inhibits apoptosis and enhances adhesion potential of bone marrow-derived endothelial progenitor cells","volume":"18","author":"Yin","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5515","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1253\/jcj.61.170","article-title":"Angiotensin-converting enzyme inhibitor up-regulates cardiac beta-receptors in cultured neonatal rat myocytes","volume":"61","author":"Yonemochi","year":"1997","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5520","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1161\/01.CIR.97.22.2268","article-title":"Mechanism of \u03b2-adrenergic receptor upregulation induced by ACE inhibition in cultured neonatal rat cardiac myocytes. Roles of bradykinin and protein kinase C","volume":"97","author":"Yonemochi","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5525","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/hr.2014.151","article-title":"Short-term use of telmisartan attenuates oxidation and improves Prdx2 expression more than antioxidant \u03b2-blockers in the cardiovascular systems of spontaneously hypertensive rats","volume":"38","author":"Yoo","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/HJH.0b013e32834000e2","article-title":"Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats","volume":"29","author":"Yoshida","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5535","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/147323000803600204","article-title":"Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicted hepatic insulin resistance via peroxisome proliferator-activated receptor-\u03b3 activation","volume":"36","author":"Yoshida","year":"2008","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5540","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1007\/s00125-006-0437-7","article-title":"Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor gamma activation","volume":"49","author":"Yoshida","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5545","doi-asserted-by":"crossref","first-page":"e81480","DOI":"10.1371\/journal.pone.0081480","article-title":"Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"8","author":"Yoshihara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-8703(94)90002-7","article-title":"Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury","volume":"128","author":"Yoshiyama","year":"1994","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5555","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.HYP.33.4.961","article-title":"Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography","volume":"33","author":"Yoshiyama","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5560","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.metabol.2011.06.007","article-title":"Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats","volume":"61","author":"Younis","year":"2012","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5565","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.metabol.2009.11.013","article-title":"Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-\u03b3 activation","volume":"59","author":"Younis","year":"2010","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5570","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00004872-199312000-00005","article-title":"The role of activated vascular angiotensin II generation in vascular hypertrophy in one-kidney, one clip hypertensive rats","volume":"11","author":"Yu","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5575","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","article-title":"Oxidative stress with an activation of the renin\u2013angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction","volume":"28","author":"Yu","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF03346544","article-title":"Effects of renin\u2013angiotensin system blockade on islet function in diabetic rats","volume":"33","author":"Yuan","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5585","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11325-014-1081-y","article-title":"Telmisartan attenuates myocardial apoptosis induced by chronic intermittent hypoxia in rats: Modulation of nitric oxide metabolism and inflammatory mediators","volume":"19","author":"Yuan","year":"2015","journal-title":"Sleep Breath"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5590","first-page":"122","article-title":"Telmisartan inhibits vasoconstriction via PPAR\u03b3-dependent expression and activation of endothelial nitric oxide synthase","volume":"90","author":"Yuen","year":"2011","journal-title":"CVR"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.03.019_bb5595","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ndt\/16.suppl_1.2","article-title":"Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?","volume":"16","author":"Zalba","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5600","first-page":"E91","article-title":"Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties","volume":"293","author":"Zanchi","year":"2007","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5605","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2261-13-39","article-title":"Telmisartan protects against microvascular dysfunction during myocardial ischemia\/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma","volume":"13","author":"Zeng","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5610","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11325-012-0669-3","article-title":"Effect of telmisartan on local cardiovascular oxidative stress in mouse under chronic intermittent hypoxia condition","volume":"17","author":"Zeng","year":"2013","journal-title":"Sleep Breath"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5615","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00165383","article-title":"Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium","volume":"347","author":"Zerkowski","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5620","doi-asserted-by":"crossref","first-page":"PL75","DOI":"10.1016\/S0024-3205(98)00278-1","article-title":"Angiotensin II signaling activiates the NO-cGMP pathway in rat proximal tubules","volume":"63","author":"Zhang","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5625","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000139051","article-title":"Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats","volume":"46","author":"Zhang","year":"1993","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5630","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00169271","article-title":"Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein","volume":"347","author":"Zhang","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5635","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10739680701743540","article-title":"Peritubular capillary loss is ameliorated by ramipril or valsartan treatment","volume":"15","author":"Zhang","year":"2008","journal-title":"Microcirculation"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5640","first-page":"712","article-title":"Expression of angiotensin converting enzyme and angiotensin II receptor in rabbits with hyperthyroid cardiomyopathy","volume":"19","author":"Zhang","year":"2007","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5645","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00045391-199705000-00006","article-title":"Comparative effects of three sites of renin\u2013angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats","volume":"4","author":"Zhang","year":"1997","journal-title":"Am J Ther"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5650","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1248\/bpb.31.2045","article-title":"Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy","volume":"31","author":"Zhang","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5655","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/BF00166950","article-title":"Positive inotropic action of angiotensin II in the pithed rat","volume":"347","author":"Zhang","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5660","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0014-2999(94)90183-X","article-title":"A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations","volume":"252","author":"Zhang","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/hr.2013.119","article-title":"Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-\u03b21\/Smad signal pathway","volume":"37","author":"Zhang","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5670","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1530\/JME-12-0020","article-title":"Telmisartan improves kidney function through inhibition of the oxidative phoshorylation pathway in diabetic rats","volume":"49","author":"Zhang","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5675","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12020-014-0239-5","article-title":"Uric acid induces oxidative stress via an activation of the renin\u2013angiotensin system in 3T3-L1 adipocytes","volume":"48","author":"Zhang","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5680","first-page":"3579","article-title":"Telmisartan inhibited angiotensin II-induced collagen metabolic imbalance without directly targeting TGF-\u03b21\/Smad signaling pathways in cardiac fibroblasts","volume":"20","author":"Zhang","year":"2014","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5685","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S0828-282X(09)70069-8","article-title":"Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration","volume":"25","author":"Zhao","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5690","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","article-title":"Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats","volume":"13","author":"Zhao","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5695","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcjd.2013.03.024","article-title":"Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: Evidence of anti-diabetes action","volume":"37","author":"Zhao","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5700","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.regpep.2010.09.005","article-title":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression","volume":"166","author":"Zhong","year":"2011","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5705","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.21.6.1035","article-title":"A novel angiotensin receptor subtype in rat mesangium. Coupling to adenylyl cyclase","volume":"21","author":"Zhou","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5710","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1291\/hypres.23.391","article-title":"Renal protective effects of blocking the intrarenal renin\u2013angiotensin system: Angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor","volume":"23","author":"Zhou","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5715","first-page":"655","article-title":"Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats","volume":"5","author":"Zhu","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1992.sp019214","article-title":"The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat","volume":"453","author":"Zhuo","year":"1992","journal-title":"J Physiol Lond"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5725","first-page":"S132","article-title":"The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure","volume":"57","author":"Ziai","year":"1996","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5730","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ajh\/hpt019","article-title":"Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan","volume":"26","author":"Zidek","year":"2013","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5735","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/aps.2011.96","article-title":"Regulation of angiotensin-(1\u20137) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure","volume":"32","author":"Zong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5740","first-page":"517","article-title":"Telmisartan protects 5\/6 Nx rats against renal injury by enhancing nNOS-derived NO generation via regulation of PPAR\u03b3 signaling","volume":"6","author":"Zou","year":"2014","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5745","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10641963.2014.943405","article-title":"TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats","volume":"37","author":"Zou","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.pharmthera.2016.03.019_bb5750","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/aps.2009.174","article-title":"PPAR\u03b3 agonists inhibit TGF-\u03b2-PKA signaling in glomerulosclerosis","volume":"31","author":"Zou","year":"2010","journal-title":"Acta Pharmacol Sin"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816300419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816300419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:09:33Z","timestamp":1748905773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816300419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":1150,"alternative-id":["S0163725816300419"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.019","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}